

Michael Berk

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5054974/publications.pdf](https://exaly.com/author-pdf/5054974/publications.pdf)

Version: 2024-02-01

1,283
papers

74,571
citations

515

124
h-index

1632

208
g-index

1431
all docs

1431
docs citations

1431
times ranked

56962
citing authors

#	ARTICLE	IF	CITATIONS
1	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 20, 97-170.	2.4	1,173
2	So depression is an inflammatory disease, but where does the inflammation come from?. <i>BMC Medicine</i> , 2013, 11, 200.	5.7	1,055
3	Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. <i>Neuroscience and Biobehavioral Reviews</i> , 2011, 35, 804-817.	6.6	1,035
4	A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 676-692.	5.0	985
5	Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 851-76.	2.1	844
6	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. <i>Bipolar Disorders</i> , 2013, 15, 1-44.	2.4	750
7	Guidelines for Developing and Reporting Machine Learning Predictive Models in Biomedical Research: A Multidisciplinary View. <i>Journal of Medical Internet Research</i> , 2016, 18, e323.	4.4	655
8	The chemistry and biological activities of N-acetylcysteine. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 4117-4129.	2.4	650
9	A randomised controlled trial of dietary improvement for adults with major depression (the "SMILES" Tj ETQq1.1 0.784314 rgB	5.7	641
10	Association of Western and Traditional Diets With Depression and Anxiety in Women. <i>American Journal of Psychiatry</i> , 2010, 167, 305-311.	8.6	605
11	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. <i>American Journal of Psychiatry</i> , 2013, 170, 1249-1262.	8.6	594
12	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. <i>Bipolar Disorders</i> , 2009, 11, 225-255.	2.4	550
13	N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia" A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2008, 64, 361-368.	1.3	495
14	Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. <i>BMC Medicine</i> , 2012, 10, 66.	5.7	494
15	N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder" A Double-Blind Randomized Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2008, 64, 468-475.	1.3	459
16	The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. <i>Molecular Psychiatry</i> , 2013, 18, 595-606.	8.1	443
17	The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. <i>Bipolar Disorders</i> , 2009, 11, 453-473.	2.4	412
18	Time for united action on depression: a Lancet" World Psychiatric Association Commission. <i>Lancet</i> , The, 2022, 399, 957-1022.	12.1	401

#	ARTICLE	IF	CITATIONS
19	N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 78-86.	2.7	389
20	Increased IgA and IgM responses against gut commensals in chronic depression: Further evidence for increased bacterial translocation or leaky gut. <i>Journal of Affective Disorders</i> , 2012, 141, 55-62.	4.2	376
21	The promise of N-acetylcysteine in neuropsychiatry. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 167-177.	8.6	367
22	Hepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease. <i>Journal of Biological Chemistry</i> , 2009, 284, 5637-5644.	3.5	365
23	Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 55, 294-321.	6.6	365
24	Potential Mechanisms of Action of Lithium in Bipolar Disorder. <i>CNS Drugs</i> , 2013, 27, 135-153.	6.1	354
25	N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1955-1962.	3.1	349
26	Ultraprocessed food and chronic noncommunicable diseases: A systematic review and meta-analysis of 43 observational studies. <i>Obesity Reviews</i> , 2021, 22, e13146.	6.8	348
27	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021, 178, 383-399.	8.6	341
28	Oxidative & nitrosative stress in depression: Why so much stress?. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 45, 46-62.	6.6	338
29	Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 41-49.	4.5	327
30	Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. <i>American Journal of Psychiatry</i> , 2016, 173, 575-587.	8.6	325
31	Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2008, 33, 2187-2199.	5.5	321
32	Diet and depression: exploring the biological mechanisms of action. <i>Molecular Psychiatry</i> , 2021, 26, 134-150.	8.1	321
33	The gut microbiome and diet in psychiatry. <i>Current Opinion in Psychiatry</i> , 2015, 28, 1-6.	6.6	313
34	New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. <i>Inflammopharmacology</i> , 2012, 20, 127-150.	3.9	291
35	Association of high-sensitivity C-reactive protein with <i>de novo</i> major depression. <i>British Journal of Psychiatry</i> , 2010, 197, 372-377.	3.5	289
36	The association between diet quality, dietary patterns and depression in adults: a systematic review. <i>BMC Psychiatry</i> , 2013, 13, 175.	2.6	288

#	ARTICLE	IF	CITATIONS
37	Lifestyle medicine for depression. <i>BMC Psychiatry</i> , 2014, 14, 107.	2.6	283
38	The validity of the 21-item version of the Depression Anxiety Stress Scales as a routine clinical outcome measure. <i>Acta Neuropsychiatrica</i> , 2007, 19, 304-310.	2.2	275
39	A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 65, 185-194.	6.6	273
40	A Prospective Study of Diet Quality and Mental Health in Adolescents. <i>PLoS ONE</i> , 2011, 6, e24805.	2.5	265
41	C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. <i>Molecular Psychiatry</i> , 2016, 21, 554-564.	8.1	265
42	Intervention in Individuals at Ultra-High Risk for Psychosis. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1206-1212.	2.3	261
43	The Association Between Habitual Diet Quality and the Common Mental Disorders in Community-Dwelling Adults. <i>Psychosomatic Medicine</i> , 2011, 73, 483-490.	2.1	258
44	Biomarkers and clinical staging in psychiatry. <i>World Psychiatry</i> , 2014, 13, 211-223.	9.6	258
45	Nutritional psychiatry: the present state of the evidence. <i>Proceedings of the Nutrition Society</i> , 2017, 76, 427-436.	1.0	257
46	The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. <i>Hepatology</i> , 2008, 47, 1495-1503.	8.1	246
47	Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Journal of Lipid Research</i> , 2010, 51, 3046-3054.	4.2	242
48	Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. <i>BMC Medicine</i> , 2015, 13, 289.	5.7	241
49	Maternal and Early Postnatal Nutrition and Mental Health of Offspring by Age 5 Years: A Prospective Cohort Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 1038-1047.	0.6	238
50	Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. <i>Biological Psychiatry</i> , 2020, 88, 369-380.	1.3	237
51	Post-Operative Cognitive Dysfunction: An exploration of the inflammatory hypothesis and novel therapies. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 84, 116-133.	6.6	233
52	Mitochondrial dysfunction in schizophrenia: Pathways, mechanisms and implications. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 48, 10-21.	6.6	232
53	Preventive psychiatry: a blueprint for improving the mental health of young people. <i>World Psychiatry</i> , 2021, 20, 200-221.	9.6	232
54	Early Intervention in Bipolar Disorder. <i>American Journal of Psychiatry</i> , 2018, 175, 411-426.	8.6	231

#	ARTICLE	IF	CITATIONS
55	Theory of mind in major depressive disorder: A meta-analysis. <i>Journal of Affective Disorders</i> , 2016, 191, 49-55.	4.2	229
56	Validity of the Hospital Anxiety and Depression Scale and Patient Health Questionnaire-9 to screen for depression in patients with coronary artery disease. <i>General Hospital Psychiatry</i> , 2007, 29, 417-424.	2.5	219
57	Clinical implications of a staging model for bipolar disorders. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 957-966.	2.8	219
58	Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. <i>British Journal of Psychiatry</i> , 2013, 202, 243-245.	3.5	214
59	The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease. <i>Molecular Neurobiology</i> , 2017, 54, 4432-4451.	4.1	213
60	Setting the stage: from prodrome to treatment resistance in bipolar disorder. <i>Bipolar Disorders</i> , 2007, 9, 671-678.	2.4	209
61	A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. <i>Molecular Psychiatry</i> , 2022, 27, 1920-1935.	8.1	209
62	Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. <i>Molecular Psychiatry</i> , 2015, 20, 1108-1119.	8.1	206
63	The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. <i>Journal of Evaluation in Clinical Practice</i> , 2008, 14, 979-983.	1.8	205
64	History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. <i>Journal of Affective Disorders</i> , 2007, 103, 181-186.	4.2	201
65	Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 321-332.	2.7	200
66	Acute phase proteins in major depression. <i>Journal of Psychosomatic Research</i> , 1997, 43, 529-534.	2.8	197
67	The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. <i>BMC Medicine</i> , 2015, 13, 68.	5.7	194
68	Tobacco smoking as a risk factor for major depressive disorder: population-based study. <i>British Journal of Psychiatry</i> , 2008, 193, 322-326.	3.5	190
69	Associations Between Diet Quality and Depressed Mood in Adolescents: Results from the Australian Healthy Neighbourhoods Study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 435-442.	2.7	190
70	Moving towards a population health approach to the primary prevention of common mental disorders. <i>BMC Medicine</i> , 2012, 10, 149.	5.7	190
71	The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2016, 22, 6152-6166.	1.8	189
72	Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1677-1681.	5.0	188

#	ARTICLE	IF	CITATIONS
73	In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neopeptides. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 344-354.	4.5	186
74	Cognitive remission: a novel objective for the treatment of major depression?. <i>BMC Medicine</i> , 2016, 14, 9.	5.7	186
75	Plasma Lysophosphatidylcholine Levels: Potential Biomarkers for Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2696-2701.	5.4	185
76	Lipid-Induced Toxicity Stimulates Hepatocytes to Release Angiogenic Microparticles That Require Vanin-1 for Uptake by Endothelial Cells. <i>Science Signaling</i> , 2013, 6, ra88.	5.2	182
77	Staging systems in bipolar disorder: an international society for bipolar disorders Task Force Report. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 354-363.	4.5	179
78	Areas of controversy in neuroprogression in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 91-103.	4.5	178
79	The Glutathione System: A New Drug Target in Neuroimmune Disorders. <i>Molecular Neurobiology</i> , 2014, 50, 1059-1084.	4.1	175
80	Mice lacking the <i>SKI</i> proto-oncogene have defects in neurulation, craniofacial patterning, and skeletal muscle development. <i>Genes and Development</i> , 1997, 11, 2029-2039.	5.8	174
81	Staging in bipolar disorder: from theoretical framework to clinical utility. <i>World Psychiatry</i> , 2017, 16, 236-244.	9.6	174
82	Neuroprogression: pathways to progressive brain changes in bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 441.	2.1	169
83	Vitamin D deficiency may play a role in depression. <i>Medical Hypotheses</i> , 2007, 69, 1316-1319.	1.5	168
84	Glutathione: a novel treatment target in psychiatry. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 346-351.	8.6	167
85	Affective and Content Analysis of Online Depression Communities. <i>IEEE Transactions on Affective Computing</i> , 2014, 5, 217-226.	8.8	167
86	Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. <i>CNS Spectrums</i> , 2016, 21, 184-198.	1.3	167
87	Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. <i>BMC Medicine</i> , 2013, 11, 74.	5.7	166
88	Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. <i>Bipolar Disorders</i> , 2011, 13, 87-98.	2.4	164
89	The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. <i>Journal of Affective Disorders</i> , 2011, 135, 389-394.	4.2	164
90	Cigarette smoking, nicotine dependence and anxiety disorders: a systematic review of population-based, epidemiological studies. <i>BMC Medicine</i> , 2012, 10, 123.	5.7	164

#	ARTICLE	IF	CITATIONS
91	The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. <i>Molecular Psychiatry</i> , 2021, 26, 4158-4178.	8.1	163
92	The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. <i>Bipolar Disorders</i> , 2009, 11, 559-595.	2.4	161
93	Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. <i>Journal of Internal Medicine</i> , 2021, 290, 621-631.	6.2	161
94	The science and practice of lithium therapy. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 192-211.	2.7	159
95	Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2016, 18, 89-101.	2.4	159
96	Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2012, 87, 135-141.	2.3	155
97	A collaborative approach to the treatment alliance in bipolar disorder. <i>Bipolar Disorders</i> , 2004, 6, 504-518.	2.4	151
98	Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. <i>Brain, Behavior, and Immunity</i> , 2013, 30, 156-167.	6.2	151
99	Mental, behavioral and neurodevelopmental disorders in the ICD-11: an international perspective on key changes and controversies. <i>BMC Medicine</i> , 2020, 18, 21.	5.7	149
100	The Efficacy of Adjunctive N-Acetylcysteine in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 628-636.	2.3	147
101	Deep learning for neuroimaging-based diagnosis and rehabilitation of Autism Spectrum Disorder: A review. <i>Computers in Biology and Medicine</i> , 2021, 139, 104949.	7.2	147
102	Psychometric properties of a short form of the Center for Epidemiologic Studies Depression (CES-D-10) scale for screening depressive symptoms in healthy community dwelling older adults. <i>General Hospital Psychiatry</i> , 2018, 51, 118-125.	2.5	146
103	The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized-controlled trials. <i>World Psychiatry</i> , 2019, 18, 308-324.	9.6	146
104	The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1366-1371.	5.0	144
105	The potential utility of a staging model as a course specifier: A bipolar disorder perspective. <i>Journal of Affective Disorders</i> , 2007, 100, 279-281.	4.2	142
106	The Elephant on the Couch: Side-Effects of Psychotherapy. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 787-794.	2.7	142
107	Is diagnosis enough to guide interventions in mental health? Using case formulation in clinical practice. <i>BMC Medicine</i> , 2012, 10, 111.	5.7	141
108	Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. <i>International Clinical Psychopharmacology</i> , 1999, 14, 339-343.	1.7	140

#	ARTICLE	IF	CITATIONS
109	Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. <i>Molecular Psychiatry</i> , 2014, 19, 750-751.	8.1	140
110	A Double-Blind, Randomized, Placebo-Controlled Trial of Augmentation With Lamotrigine or Placebo in Patients Concomitantly Treated With Fluoxetine for Resistant Major Depressive Episodes. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 403-407.	2.3	140
111	Annual high-dose vitamin D ₃ and mental well-being: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2011, 198, 357-364.	3.5	139
112	Meta-analytic review of neurocognition in bipolar II disorder. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 165-174.	4.5	139
113	Loss of the SKI proto-oncogene in individuals affected with 1p36 deletion syndrome is predicted by strain-dependent defects in <i>Ski</i> ^{-/-} mice. <i>Nature Genetics</i> , 2002, 30, 106-109.	20.2	138
114	Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 769-783.	5.0	138
115	Stage managing bipolar disorder. <i>Bipolar Disorders</i> , 2014, 16, 471-477.	2.4	138
116	Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. <i>Laboratory Investigation</i> , 2012, 92, 713-723.	3.9	136
117	Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. <i>Neuroscience Letters</i> , 2007, 420, 45-48.	2.1	135
118	Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. <i>Molecular Psychiatry</i> , 2015, 20, 695-702.	8.1	135
119	Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 42, 1-4.	5.0	133
120	How cigarette smoking may increase the risk of anxiety symptoms and anxiety disorders: a critical review of biological pathways. <i>Brain and Behavior</i> , 2013, 3, 302-326.	2.3	131
121	Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. <i>BMC Medicine</i> , 2015, 13, 28.	5.7	131
122	Executive functioning and theory of mind in euthymic bipolar disorder. <i>Bipolar Disorders</i> , 2005, 7, 43-52.	2.4	129
123	The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. <i>Bipolar Disorders</i> , 2007, 9, 571-579.	2.4	127
124	Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 512-529.	2.7	127
125	Mitochondrial dysfunction in bipolar disorder: Evidence, pathophysiology and translational implications. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 68, 694-713.	6.6	127
126	A model of the mitochondrial basis of bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 1-20.	6.6	125

#	ARTICLE	IF	CITATIONS
127	Deep brain stimulation for treatment-resistant depression: Efficacy, safety and mechanisms of action. <i>Neuroscience and Biobehavioral Reviews</i> , 2012, 36, 1920-1933.	6.6	124
128	Targeting classical IL-6 signalling or IL-6<i>trans</i>-signalling in depression?. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 495-512.	3.4	124
129	Risk stratification using data from electronic medical records better predicts suicide risks than clinician assessments. <i>BMC Psychiatry</i> , 2014, 14, 76.	2.6	124
130	Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists. <i>Molecular Neurobiology</i> , 2018, 55, 5767-5786.	4.1	122
131	Exercising the worry away: How inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 573-584.	6.6	121
132	Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neurodegenerative diseases. <i>Behavioural Brain Research</i> , 2018, 341, 154-175.	2.3	120
133	The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases. <i>Molecular Neurobiology</i> , 2016, 53, 1195-1219.	4.1	118
134	Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes. <i>FASEB Journal</i> , 2020, 34, 8787-8795.	0.4	118
135	Enhancing medication adherence in patients with bipolar disorder. <i>Human Psychopharmacology</i> , 2010, 25, 1-16.	1.7	117
136	Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. <i>Molecular Psychiatry</i> , 2012, 17, 1150-1152.	8.1	116
137	Systematic assessment of environmental risk factors for bipolar disorder: an umbrella review of systematic reviews and meta-analyses. <i>Bipolar Disorders</i> , 2017, 19, 84-96.	2.4	116
138	The Dietary Inflammatory Index and Human Health: An Umbrella Review of Meta-Analyses of Observational Studies. <i>Advances in Nutrition</i> , 2021, 12, 1681-1690.	6.4	116
139	Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. <i>Translational Psychiatry</i> , 2020, 10, 152.	4.9	115
140	KiSS1 Suppresses Metastasis in Human Ovarian Cancer via Inhibition of Protein Kinase C Alpha. <i>Clinical and Experimental Metastasis</i> , 2005, 22, 369-376.	3.5	114
141	Cytochrome <i>c</i> P450s from the fall armyworm (<i>S. podoptera frugiperda</i>): responses to plant allelochemicals and pesticides. <i>Insect Molecular Biology</i> , 2015, 24, 115-128.	1.9	113
142	Psychosocial therapies for the adjunctive treatment of bipolar disorder in adults: Network meta-analysis. <i>British Journal of Psychiatry</i> , 2017, 210, 333-341.	3.5	113
143	Group-based psychosocial intervention for bipolar disorder: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2010, 196, 383-388.	3.5	112
144	Symptomatic and functional outcome 12 months after a first episode of psychotic mania: barriers to recovery in a catchment area sample. <i>Bipolar Disorders</i> , 2006, 8, 221-231.	2.4	111

#	ARTICLE	IF	CITATIONS
145	Evidence and implications for early intervention in bipolar disorder. <i>Journal of Mental Health</i> , 2010, 19, 113-126.	2.2	111
146	Clinical practice recommendations for bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 27-46.	4.5	110
147	Effects of Enforcement of Youth Access Laws on Smoking Prevalence. <i>American Journal of Community Psychology</i> , 1999, 27, 143-160.	2.3	109
148	To combine or not to combine? A literature review of antidepressant combination therapy. <i>Journal of Affective Disorders</i> , 2005, 89, 1-11.	4.2	109
149	Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1416-1423.	2.3	109
150	Diet as a hot topic in psychiatry: a population-scale study of nutritional intake and inflammatory potential in severe mental illness. <i>World Psychiatry</i> , 2018, 17, 365-367.	9.6	109
151	Th17 Pathway-Mediated Immunopathogenesis of Schizophrenia: Mechanisms and Implications. <i>Schizophrenia Bulletin</i> , 2014, 40, 1412-1421.	4.5	108
152	Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation. <i>Neurobiology of Disease</i> , 2009, 33, 354-357.	4.5	107
153	Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. <i>Psychoneuroendocrinology</i> , 2010, 35, 1142-1147.	2.8	107
154	A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults. <i>Journal of Affective Disorders</i> , 2010, 127, 316-320.	4.2	107
155	Caspase 3 Inactivation Protects Against Hepatic Cell Death and Ameliorates Fibrogenesis in a Diet-Induced NASH Model. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1197-1206.	2.4	107
156	Relationship between serotonin and the Temperament and Character Inventory. <i>Psychiatry Research</i> , 1999, 89, 29-37.	3.4	106
157	Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. <i>Journal of Affective Disorders</i> , 2013, 150, 923-930.	4.2	106
158	The predictive validity of bipolar at-risk (prodromal) criteria in help-seeking adolescents and young adults: a prospective study. <i>Bipolar Disorders</i> , 2014, 16, 493-504.	2.4	106
159	The effects of physical activity in the acute treatment of bipolar disorder: A pilot study. <i>Journal of Affective Disorders</i> , 2007, 101, 259-262.	4.2	105
160	Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials. <i>Journal of Affective Disorders</i> , 2016, 200, 235-242.	4.2	105
161	Bipolar II disorder: a review. <i>Bipolar Disorders</i> , 2005, 7, 11-21.	2.4	104
162	Depression and chronic diseases: Co-occurrence and communality of risk factors. <i>Journal of Affective Disorders</i> , 2018, 241, 461-468.	4.2	103

#	ARTICLE	IF	CITATIONS
163	Are illness perceptions about coronary artery disease predictive of depression and quality of life outcomes?. <i>Journal of Psychosomatic Research</i> , 2009, 66, 211-220.	2.8	102
164	The renin-angiotensin system: a possible new target for depression. <i>BMC Medicine</i> , 2017, 15, 144.	5.7	102
165	Adipokines as emerging depression biomarkers: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2014, 59, 28-37.	3.2	101
166	Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. <i>Molecular Psychiatry</i> , 2015, 20, 152-153.	8.1	101
167	Comparison of self-report and structured clinical interview in the identification of depression. <i>Comprehensive Psychiatry</i> , 2014, 55, 866-869.	3.3	100
168	A systematic review and meta-analysis of prospective transition from major depression to bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2017, 135, 273-284.	4.5	100
169	N-acetylcysteine for major depressive episodes in bipolar disorder. <i>Revista Brasileira De Psiquiatria</i> , 2011, 33, 374-378.	2.7	99
170	Leaky brain in neurological and psychiatric disorders: Drivers and consequences. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 924-948.	2.7	99
171	Peripheral levels of C-reactive protein, tumor necrosis factor- α , interleukin-6, and interleukin-1 β across the mood spectrum in bipolar disorder: A meta-analysis of mean differences and variability. <i>Brain, Behavior, and Immunity</i> , 2021, 97, 193-203.	6.2	99
172	Increased autoimmune activity against 5-HT: A key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. <i>Journal of Affective Disorders</i> , 2012, 136, 386-392.	4.2	98
173	A Head-to-Head Comparison of Aripiprazole and Risperidone for Safety and Treating Autistic Disorders, a Randomized Double Blind Clinical Trial. <i>Child Psychiatry and Human Development</i> , 2014, 45, 185-192.	2.1	98
174	Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. <i>International Clinical Psychopharmacology</i> , 2008, 23, 84-87.	1.7	97
175	Prevalence of mood and anxiety disorder in self reported irritable bowel syndrome (IBS). An epidemiological population based study of women. <i>BMC Gastroenterology</i> , 2010, 10, 88.	1.9	97
176	Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. <i>Schizophrenia Research</i> , 2010, 119, 1-10.	2.0	97
177	Selective Serotonin Reuptake Inhibitors Inhibit Human Osteoclast and Osteoblast Formation and Function. <i>Biological Psychiatry</i> , 2013, 74, 32-39.	1.3	97
178	Biological phenotypes underpin the psychosomatic symptoms of somatization, depression, and chronic fatigue syndrome. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 83-97.	4.5	97
179	A shared framework for the common mental disorders and Non-Communicable Disease: key considerations for disease prevention and control. <i>BMC Psychiatry</i> , 2015, 15, 15.	2.6	97
180	The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary. <i>Bipolar Disorders</i> , 2020, 22, 805-821.	2.4	96

#	ARTICLE	IF	CITATIONS
181	&Nt;/em>-Acetylcysteine in Depressive Symptoms and Functionality. Journal of Clinical Psychiatry, 2016, 77, e457-e466.	2.3	96
182	N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. Journal of Affective Disorders, 2011, 129, 317-320.	4.2	95
183	Risk of dementia in bipolar disorder and the interplay of lithium: a systematic review and metaâ€œanalyses. Acta Psychiatrica Scandinavica, 2020, 141, 510-521.	4.5	95
184	The effect of macroeconomic variables on suicide. Psychological Medicine, 2006, 36, 181-189.	5.2	94
185	(Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: From antioxidants to kinase inhibitors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 659-663.	5.0	94
186	Habitual physical activity and the risk for depressive and anxiety disorders among older men and women. International Psychogeriatrics, 2011, 23, 292-298.	1.1	94
187	The Emerging Role of Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/cfs). Molecular Neurobiology, 2014, 49, 741-756.	4.1	94
188	Altered cardiac autonomic nervous function in depression. BMC Psychiatry, 2013, 13, 187.	2.6	93
189	Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than <i>Clostridium difficile</i> infection: a systematic review and meta-analysis. Gut Microbes, 2020, 12, 1854640.	10.3	93
190	Lifestyle management of unipolar depression. Acta Psychiatrica Scandinavica, 2013, 127, 38-54.	4.5	92
191	The proximal prodrome to first episode mania â€œ a new target for early intervention. Bipolar Disorders, 2008, 10, 555-565.	2.4	91
192	The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis. Sleep Medicine Reviews, 2018, 41, 255-265.	9.4	91
193	Results of the COVID-19 mental health international for the general population (COMET-G) study. European Neuropsychopharmacology, 2022, 54, 21-40.	1.6	91
194	A review of clozapine safety. Expert Opinion on Drug Safety, 2005, 4, 731-744.	2.5	90
195	Putative neuroprotective agents in neuropsychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 42, 135-145.	5.0	90
196	Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. International Clinical Psychopharmacology, 2001, 16, 87-92.	1.7	89
197	Leptin in depressed women: Cross-sectional and longitudinal data from an epidemiologic study. Journal of Affective Disorders, 2008, 107, 221-225.	4.2	89
198	Diet quality in bipolar disorder in a population-based sample of women. Journal of Affective Disorders, 2011, 129, 332-337.	4.2	89

#	ARTICLE	IF	CITATIONS
199	Oxidative stress and inflammatory markers are associated with depression and nicotine dependence. <i>Neuroscience Letters</i> , 2013, 544, 136-140.	2.1	89
200	DSM-5: a collection of psychiatrist views on the changes, controversies, and future directions. <i>BMC Medicine</i> , 2013, 11, 202.	5.7	89
201	Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 13, 1819-1835.	1.5	89
202	Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. <i>ELife</i> , 2017, 6, .	5.9	89
203	Serological observations in patients suffering from acute manic episodes. <i>Human Psychopharmacology</i> , 2002, 17, 175-179.	1.7	88
204	Dietary intake of fish and PUFA, and clinical depressive and anxiety disorders in women. <i>British Journal of Nutrition</i> , 2013, 109, 2059-2066.	2.6	88
205	Cognitive effects of adjunctive N-acetyl cysteine in psychosis. <i>Psychological Medicine</i> , 2017, 47, 866-876.	5.2	88
206	The effect of N-acetylcysteine (NAC) on human cognition – A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 78, 44-56.	6.6	88
207	Dietary selenium and major depression: a nested case-control study. <i>Complementary Therapies in Medicine</i> , 2012, 20, 119-123.	2.8	87
208	Depression is a risk factor for incident coronary heart disease in women: An 18-year longitudinal study. <i>Journal of Affective Disorders</i> , 2016, 196, 117-124.	4.2	86
209	Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. <i>Journal of Affective Disorders</i> , 2015, 172, 55-62.	4.2	85
210	Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. <i>Frontiers in Psychiatry</i> , 2019, 10, 103.	2.7	85
211	Ovarian Cancer G Protein Coupled Receptor 1, a New Metastasis Suppressor Gene in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1313-1327.	6.3	84
212	Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: Implications for the pathways to chronic depression and neuroprogression. <i>Journal of Affective Disorders</i> , 2013, 149, 23-29.	4.2	84
213	Nitrosative Stress, Hypernitrosylation, and Autoimmune Responses to Nitrosylated Proteins: New Pathways in Neuroprogressive Disorders Including Depression and Chronic Fatigue Syndrome. <i>Molecular Neurobiology</i> , 2017, 54, 4271-4291.	4.1	84
214	Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 1058-1067.	2.7	83
215	Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. <i>BMC Medicine</i> , 2012, 10, 91.	5.7	83
216	Coenzyme Q10 Depletion in Medical and Neuropsychiatric Disorders: Potential Repercussions and Therapeutic Implications. <i>Molecular Neurobiology</i> , 2013, 48, 883-903.	4.1	83

#	ARTICLE	IF	CITATIONS
217	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. <i>Life Sciences</i> , 2020, 258, 118166.	4.4	83
218	The Use of Statins After a Cardiac Intervention Is Associated With Reduced Risk of Subsequent Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1229-1235.	2.3	83
219	Comorbid depression and health-related quality of life in patients with coronary artery disease. <i>Journal of Psychosomatic Research</i> , 2007, 62, 401-410.	2.8	82
220	Clinical practice recommendations for depression. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 8-26.	4.5	82
221	A Role for Glutathione in the Pathophysiology of Bipolar Disorder and Schizophrenia? Animal Models and Relevance to Clinical Practice. <i>Current Medicinal Chemistry</i> , 2009, 16, 2965-2976.	2.4	82
222	Omega-6 to omega-3 polyunsaturated fatty acid ratio and subsequent mood disorders in young people with at-risk mental states: a 7-year longitudinal study. <i>Translational Psychiatry</i> , 2017, 7, e1220-e1220.	4.9	82
223	What we learn about bipolar disorder from large-scale neuroimaging: Findings and future directions from the ENIGMA Bipolar Disorder Working Group. <i>Human Brain Mapping</i> , 2022, 43, 56-82.	3.7	82
224	Lamotrigine Compared with Lithium in Mania: A Double-Blind Randomized Controlled Trial. <i>Annals of Clinical Psychiatry</i> , 2000, 12, 5-10.	1.5	81
225	Role of Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways in the Etiology of Depression: Therapeutic Implications. <i>CNS Drugs</i> , 2014, 28, 1-10.	6.1	81
226	Youth self-harm in low- and middle-income countries: Systematic review of the risk and protective factors. <i>International Journal of Social Psychiatry</i> , 2017, 63, 359-375.	3.3	81
227	Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification. <i>BMC Nephrology</i> , 2018, 19, 305.	1.8	81
228	Toward Precision Psychiatry in Bipolar Disorder: Staging 2.0. <i>Frontiers in Psychiatry</i> , 2018, 9, 641.	2.7	81
229	Shared pathways for neuroprogression and somatoprogession in neuropsychiatric disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 862-882.	6.6	81
230	Abnormalities in Osteoclastogenesis and Decreased Tumorigenesis in Mice Deficient for Ovarian Cancer G Protein-Coupled Receptor 1. <i>PLoS ONE</i> , 2009, 4, e5705.	2.5	81
231	Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume. <i>Translational Psychiatry</i> , 2017, 7, e1011-e1011.	4.9	80
232	Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 829-840.	2.7	80
233	Gut Permeability and Microbiota in Parkinson's Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways. <i>Current Pharmaceutical Design</i> , 2016, 22, 6142-6151.	1.8	80
234	Pretreatment and outcome correlates of past sexual and physical trauma in 118 bipolar I disorder patients with a first episode of psychotic mania. <i>Bipolar Disorders</i> , 2010, 12, 244-252.	2.4	79

#	ARTICLE	IF	CITATIONS
235	Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. <i>Acta Psychiatrica Scandinavica</i> , 2012, 125, 303-308.	4.5	79
236	Prevention of common mental disorders: What can we learn from those who have gone before and where do we go next?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 920-929.	2.7	79
237	N-Acetyl Cysteine in the Treatment of Obsessive Compulsive and Related Disorders: A Systematic Review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 12-24.	2.1	79
238	Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women. <i>JAMA Psychiatry</i> , 2016, 73, 947.	11.3	79
239	A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. <i>BMC Medicine</i> , 2019, 17, 18.	5.7	79
240	A functional MRI study of Theory of Mind in euthymic bipolar disorder patients. <i>Bipolar Disorders</i> , 2008, 10, 943-956.	2.4	78
241	The empirical redefinition of the psychometric criteria for remission in bipolar disorder. <i>Journal of Affective Disorders</i> , 2008, 106, 153-158.	4.2	78
242	Integrating Early Intervention for Borderline Personality Disorder and Mood Disorders. <i>Harvard Review of Psychiatry</i> , 2016, 24, 330-341.	2.2	78
243	Population prevalence of personality disorder and associations with physical health comorbidities and health care service utilization: A review.. <i>Personality Disorders: Theory, Research, and Treatment</i> , 2016, 7, 136-146.	1.2	78
244	Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes. <i>Current Pharmaceutical Design</i> , 2016, 22, 6087-6106.	1.8	78
245	Going up in smoke: Tobacco smoking is associated with worse treatment outcomes in mania. <i>Journal of Affective Disorders</i> , 2008, 110, 126-134.	4.2	77
246	Predominant polarity as a course specifier for bipolar disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2014, 163, 56-64.	4.2	77
247	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 720-740.	2.4	77
248	Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytochemicals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 424-455.	2.7	77
249	Early intervention in bipolar disorders: Clinical, biochemical and neuroimaging imperatives. <i>Journal of Affective Disorders</i> , 2009, 114, 1-13.	4.2	76
250	N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder. <i>Neuroscience Letters</i> , 2011, 499, 149-153.	2.1	76
251	Could Alzheimer's Disease Originate in the Periphery and If So How So?. <i>Molecular Neurobiology</i> , 2019, 56, 406-434.	4.1	76
252	Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. <i>BMC Medicine</i> , 2020, 18, 261.	5.7	76

#	ARTICLE	IF	CITATIONS
253	Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression. <i>Pharmacological Reports</i> , 2013, 65, 1647-1654.	3.3	75
254	The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1336-1345.	6.6	75
255	T helper 17 cells may drive neuroprogression in major depressive disorder: Proposal of an integrative model. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 64, 83-100.	6.6	75
256	The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence. <i>Nutrients</i> , 2019, 11, 1196.	4.2	74
257	Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder. <i>Current Pharmaceutical Design</i> , 2012, 18, 358-375.	1.8	73
258	Depressive symptoms in first episode schizophrenia spectrum disorder. <i>Schizophrenia Research</i> , 2012, 134, 20-26.	2.0	73
259	Effect of Chronic N-Acetyl Cysteine Administration on Oxidative Status in the Presence and Absence of Induced Oxidative Stress in Rat Striatum. <i>Neurochemical Research</i> , 2008, 33, 508-517.	3.3	72
260	Does dopamine dysfunction drive depression?. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 116-124.	4.5	71
261	Serum Retinol-binding Protein 4 Levels in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 985-989.	2.3	71
262	Diet quality and mental health problems in adolescents from East London: a prospective study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2013, 48, 1297-1306.	3.3	71
263	Mechanisms Underlying Neurocognitive Dysfunctions in Recurrent Major Depression. <i>Medical Science Monitor</i> , 2015, 21, 1535-1547.	1.1	71
264	The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes. <i>Clinical Therapeutics</i> , 2017, 39, 477-486.	2.3	71
265	The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary. <i>Bipolar Disorders</i> , 2020, 22, 788-804.	2.4	71
266	The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment. <i>Frontiers in Psychiatry</i> , 2021, 12, 546801.	2.7	71
267	Atopic disorders and depression: Findings from a large, population-based study. <i>Journal of Affective Disorders</i> , 2014, 155, 261-265.	4.2	70
268	Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2015, 62, 18-26.	2.8	70
269	Sarcopenia and the Common Mental Disorders: a Potential Regulatory Role of Skeletal Muscle on Brain Function?. <i>Current Osteoporosis Reports</i> , 2015, 13, 351-357.	3.5	70
270	The association between dietary patterns, diabetes and depression. <i>Journal of Affective Disorders</i> , 2015, 174, 215-224.	4.2	70

#	ARTICLE	IF	CITATIONS
271	Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism smoking interactions differentially predict the odds of major depression and bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 159, 23-30.	4.2	69
272	<i>N</i> -acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 391-400.	4.5	69
273	The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. <i>Lancet Psychiatry</i> , 2019, 6, 735-744.	7.6	69
274	Early intervention in bipolar disorders: opportunities and pitfalls. <i>Medical Journal of Australia</i> , 2007, 187, S11-4.	1.7	68
275	Lower levels of physical activity in childhood associated with adult depression. <i>Journal of Science and Medicine in Sport</i> , 2011, 14, 222-226.	1.2	68
276	Don't Worry, be Active: Positive Affect and Habitual Physical Activity. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 1047-1052.	2.7	68
277	Nutritional Deficiencies and Clinical Correlates in First-Episode Psychosis: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2018, 44, 1275-1292.	4.5	68
278	The limitations of using randomised controlled trials as a basis for developing treatment guidelines. <i>Evidence-Based Mental Health</i> , 2018, 21, 4-6.	5.4	68
279	The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?. <i>Cytokine</i> , 2021, 144, 155593.	3.2	68
280	Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. <i>Journal of Affective Disorders</i> , 2009, 119, 22-27.	4.2	67
281	The impact of statins on psychological wellbeing: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2012, 10, 154.	5.7	67
282	The relationships between insomnia, sleep apnoea and depression: Findings from the American National Health and Nutrition Examination Survey, 2005-2008. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 156-170.	2.7	67
283	Towards recovery-oriented psychosocial interventions for bipolar disorder: Quality of life outcomes, stage-sensitive treatments, and mindfulness mechanisms. <i>Clinical Psychology Review</i> , 2017, 52, 148-163.	12.0	67
284	Meta-analysis of randomised controlled trials with <i>N</i> -acetylcysteine in the treatment of schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 453-466.	2.7	67
285	Fusing Data Mining, Machine Learning and Traditional Statistics to Detect Biomarkers Associated with Depression. <i>PLoS ONE</i> , 2016, 11, e0148195.	2.5	67
286	Depression and bone mineral density in a community sample of perimenopausal women: Geelong Osteoporosis Study. <i>Menopause</i> , 2005, 12, 88-91.	2.0	66
287	Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice. <i>Behavioural Brain Research</i> , 2009, 198, 258-262.	2.3	66
288	Characterisation of the prodrome to a first episode of psychotic mania: Results of a retrospective study. <i>Journal of Affective Disorders</i> , 2010, 124, 341-345.	4.2	66

#	ARTICLE	IF	CITATIONS
289	Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 42, 101-114.	5.0	66
290	Systematic review of N-acetylcysteine in the treatment of addictions. <i>Revista Brasileira De Psiquiatria</i> , 2014, 36, 168-175.	2.7	66
291	Statin use and risk of depression: a Swedish national cohort study. <i>BMC Psychiatry</i> , 2014, 14, 348.	2.6	66
292	Neurodevelopmental pathways in bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 112, 213-226.	6.6	66
293	The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. <i>Current Neuropharmacology</i> , 2021, 19, 1202-1224.	3.0	66
294	DNA damage in rats after treatment with methylphenidate. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1282-1288.	5.0	65
295	ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. <i>Translational Psychiatry</i> , 2012, 2, e198-e198.	4.9	65
296	Food policies for physical and mental health. <i>BMC Psychiatry</i> , 2014, 14, 132.	2.6	65
297	The impact of maternal smoking during pregnancy on depressive and anxiety behaviors in children: the Norwegian Mother and Child Cohort Study. <i>BMC Medicine</i> , 2015, 13, 24.	5.7	65
298	The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2017, 47, 1515-1527.	5.2	65
299	Perturbations in the apoptotic pathway and mitochondrial network dynamics in peripheral blood mononuclear cells from bipolar disorder patients. <i>Translational Psychiatry</i> , 2017, 7, e1111-e1111.	4.9	65
300	Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. <i>Nutrition Reviews</i> , 2019, 77, 557-571.	5.9	65
301	The Endoplasmic Reticulum Stress Response in Neuroprogressive Diseases: Emerging Pathophysiological Role and Translational Implications. <i>Molecular Neurobiology</i> , 2018, 55, 8765-8787.	4.1	64
302	Dietary Omega-3 Fatty Acids and Depression in a Community Sample. <i>Nutritional Neuroscience</i> , 2004, 7, 101-106.	3.0	63
303	Efficacy and Adverse Effects of Venlafaxine in Children and Adolescents with ADHD: A Systematic Review of Non-controlled and Controlled Trials. <i>Reviews on Recent Clinical Trials</i> , 2013, 8, 2-8.	0.9	63
304	A randomized head to head trial of MoodSwings.net.au: An internet based self-help program for bipolar disorder. <i>Journal of Affective Disorders</i> , 2015, 171, 13-21.	4.2	63
305	Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking. <i>Pharmacotherapy</i> , 2018, 38, 235-258.	2.6	63
306	Prevalence of depressive symptoms and its associated factors among healthy community-dwelling older adults living in Australia and the United States. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1208-1216.	2.6	63

#	ARTICLE	IF	CITATIONS
307	Complementary Medicine, Exercise, Meditation, Diet, and Lifestyle Modification for Anxiety Disorders: A Review of Current Evidence. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-20.	1.2	62
308	A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior. <i>BMC Medicine</i> , 2013, 11, 64.	5.7	62
309	Stearoyl-CoA desaturase plays an important role in proliferation and chemoresistance in human hepatocellular carcinoma. <i>Journal of Surgical Research</i> , 2014, 186, 29-38.	1.6	62
310	N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study. <i>Redox Report</i> , 2015, 20, 215-222.	4.6	62
311	Fetal programming of schizophrenia: Select mechanisms. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 49, 90-104.	6.6	62
312	Differences in the immune-inflammatory profiles of unipolar and bipolar depression. <i>Journal of Affective Disorders</i> , 2020, 262, 8-15.	4.2	62
313	Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression?. <i>Medical Hypotheses</i> , 2005, 65, 39-43.	1.5	61
314	Depression and pain: an overview. <i>Acta Neuropsychiatrica</i> , 2006, 18, 79-87.	2.2	61
315	Transcriptional Profile of Genes Involved in Oxidative Stress and Antioxidant Defense in a Dietary Murine Model of Steatohepatitis. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 437-445.	5.4	61
316	Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. <i>Molecular Psychiatry</i> , 2014, 19, 317-324.	8.1	61
317	Prevalence of excessive daytime sleepiness in a sample of the Australian adult population. <i>Sleep Medicine</i> , 2014, 15, 348-354.	2.3	61
318	N-acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis. <i>American Journal on Addictions</i> , 2017, 26, 660-666.	1.9	61
319	Differential effect of quetiapine and lithium on functional connectivity of the striatum in first episode mania. <i>Translational Psychiatry</i> , 2018, 8, 59.	4.9	61
320	Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. <i>Human Psychopharmacology</i> , 2009, 24, 233-238.	1.7	60
321	Estudios normativos españoles en población adulta joven (Proyecto NEURONORMA jóvenes): Metodología y características de la muestra. <i>Neurología</i> , 2012, 27, 253-260.	0.9	60
322	DSM-5 mixed specifier for manic episodes: Evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. <i>Journal of Affective Disorders</i> , 2013, 150, 378-383.	4.2	60
323	N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study. <i>CNS Drugs</i> , 2015, 29, 801-809.	6.1	60
324	A Review of the Theoretical and Biological Understanding of the Nocebo and Placebo Phenomena. <i>Clinical Therapeutics</i> , 2017, 39, 469-476.	2.3	60

#	ARTICLE	IF	CITATIONS
325	Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools. <i>BMC Psychiatry</i> , 2017, 17, 60.	2.6	60
326	Multiple Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways Explain the Frequent Presence of Depression in Multiple Sclerosis. <i>Molecular Neurobiology</i> , 2018, 55, 6282-6306.	4.1	60
327	New drug candidates for depression – a nationwide population-based study. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 68-77.	4.5	60
328	The platelet as a peripheral marker in psychiatric illness. <i>Human Psychopharmacology</i> , 2001, 16, 229-236.	1.7	59
329	Online mindfulness-based intervention for late-stage bipolar disorder: pilot evidence for feasibility and effectiveness. <i>Journal of Affective Disorders</i> , 2015, 178, 46-51.	4.2	59
330	Cognitive impairment in first-episode mania: a systematic review of the evidence in the acute and remission phases of the illness. <i>International Journal of Bipolar Disorders</i> , 2015, 3, 9.	2.2	59
331	Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. <i>British Journal of Psychiatry</i> , 2019, 214, 27-35.	3.5	58
332	Is Lithium in a Class of Its Own? A Brief Profile of Its Clinical Use. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 1096-1104.	2.7	57
333	Endothelial dysfunction in neuroprogressive disorders – causes and suggested treatments. <i>BMC Medicine</i> , 2020, 18, 305.	5.7	57
334	Social isolation, social support and loneliness as predictors of cardiovascular disease incidence and mortality. <i>BMC Geriatrics</i> , 2021, 21, 711.	2.8	57
335	Platelet Glutamate Receptor Supersensitivity in Major Depressive Disorder. <i>Clinical Neuropharmacology</i> , 2001, 24, 129-132.	0.7	56
336	Lifetime psychiatric disorders and body composition: A population-based study. <i>Journal of Affective Disorders</i> , 2009, 118, 173-179.	4.2	56
337	A critical update on psychological interventions for bipolar disorders. <i>Current Psychiatry Reports</i> , 2009, 11, 494-502.	4.5	56
338	A randomised, controlled trial of a dietary intervention for adults with major depression (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222	2.6	56
339	A brief review of exercise, bipolar disorder, and mechanistic pathways. <i>Frontiers in Psychology</i> , 2015, 6, 147.	2.2	56
340	Personality disorders and physical comorbidities in adults from the United States: data from the National Epidemiologic Survey on Alcohol and Related Conditions. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2015, 50, 807-820.	3.3	56
341	Bias in emerging biomarkers for bipolar disorder. <i>Psychological Medicine</i> , 2016, 46, 2287-2297.	5.2	56
342	The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. <i>Life Sciences</i> , 2000, 66, 2427-2432.	4.4	55

#	ARTICLE	IF	CITATIONS
343	Pure and mixed manic subtypes: a review of diagnostic classification and validation. <i>Bipolar Disorders</i> , 2008, 10, 131-143.	2.4	55
344	Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. <i>European Journal of Pharmacology</i> , 2010, 649, 224-228.	3.6	55
345	Do Comorbid Anxiety Disorders Moderate the Effects of Psychotherapy for Bipolar Disorder? Results From STEP-BD. <i>American Journal of Psychiatry</i> , 2014, 171, 178-186.	8.6	55
346	The association between poor dental health and depression: findings from a large-scale, population-based study (the NHANES study). <i>General Hospital Psychiatry</i> , 2014, 36, 266-270.	2.5	55
347	Olanzapine/Fluoxetine Combination for the Treatment of Mixed Depression in Bipolar I Disorder. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1424-1431.	2.3	55
348	The effects of escitalopram on myocardial apoptosis and the expression of Bax and Bcl-2 during myocardial ischemia/reperfusion in a model of rats with depression. <i>BMC Psychiatry</i> , 2014, 14, 349.	2.6	54
349	Castelli risk indexes 1 and 2 are higher in major depression but other characteristics of the metabolic syndrome are not specific to mood disorders. <i>Life Sciences</i> , 2014, 102, 65-71.	4.4	54
350	Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: An accelerated aging biomarker?. <i>Journal of Affective Disorders</i> , 2015, 182, 64-69.	4.2	54
351	Quetiapine<i>v.</i>lithium in the maintenance phase following a first episode of mania: Randomised controlled trial. <i>British Journal of Psychiatry</i> , 2017, 210, 413-421.	3.5	54
352	Female Leadership and Gender Gap within Firms: Evidence from an Italian Board Reform. <i>ILR Review</i> , 2022, 75, 488-515.	2.5	54
353	Prebiotics, probiotics, fermented foods and cognitive outcomes: A meta-analysis of randomized controlled trials. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 118, 472-484.	6.6	54
354	Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. <i>Annals of Clinical Psychiatry</i> , 2000, 12, 5-10.	1.5	54
355	Major psychoses with mixed psychotic and mood symptoms: are mixed psychoses associated with different neurobiological markers?. <i>Acta Psychiatrica Scandinavica</i> , 2008, 118, 172-187.	4.5	53
356	Nail-Biting Stuff? The Effect of N-acetyl Cysteine on Nail-Biting. <i>CNS Spectrums</i> , 2009, 14, 357-360.	1.3	53
357	Pop, heavy metal and the blues: secondary analysis of persistent organic pollutants (POP), heavy metals and depressive symptoms in the NHANES National Epidemiological Survey. <i>BMJ Open</i> , 2014, 4, e005142.	2.1	53
358	N-acetylcysteine Versus Placebo for Treating Nail Biting, a Double Blind Randomized Placebo Controlled Clinical Trial. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2013, 12, 223-228.	1.0	53
359	Scale matters: the need for a Bipolar Depression Rating Scale (BDRS). <i>Acta Psychiatrica Scandinavica</i> , 2004, 110, 39-45.	4.5	52
360	Inflammation-Related Disorders in the Tryptophan Catabolite Pathway in Depression and Somatization. <i>Advances in Protein Chemistry and Structural Biology</i> , 2012, 88, 27-48.	0.5	52

#	ARTICLE	IF	CITATIONS
361	Immuno-psychiatry: an agenda for clinical practice and innovative research. <i>BMC Medicine</i> , 2016, 14, 173.	5.7	52
362	Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?. <i>Metabolic Brain Disease</i> , 2019, 34, 385-415.	2.9	52
363	Antihypertensive Drugs and Risk of Depression. <i>Hypertension</i> , 2020, 76, 1263-1279.	4.9	52
364	Monitoring the Safe Use of Clozapine. <i>CNS Drugs</i> , 2007, 21, 117-127.	6.1	51
365	The role of psychotherapy in bipolar disorder. <i>Medical Journal of Australia</i> , 2010, 193, S31-5.	1.7	51
366	Palliative models of care for later stages of mental disorder: maximizing recovery, maintaining hope, and building morale. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 92-99.	2.7	51
367	Effects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression. <i>Drugs and Aging</i> , 2016, 33, 21-25.	2.9	51
368	Nutritional value of barley cereal and better opportunities for its processing as a value-added food: a comprehensive review. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 1092-1104.	10.0	51
369	Effect of Aspirin vs Placebo on the Prevention of Depression in Older People. <i>JAMA Psychiatry</i> , 2020, 77, 1012.	11.3	51
370	Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry. <i>Molecular Neurobiology</i> , 2021, 58, 2158-2182.	4.1	51
371	Fluoxetine treatment of acral lick dermatitis in dogs: A placebo-controlled randomized double blind trial. <i>Depression and Anxiety</i> , 1998, 8, 21-23.	4.1	50
372	Illness Beliefs About Heart Disease and Adherence to Secondary Prevention Regimens. <i>Psychosomatic Medicine</i> , 2008, 70, 942-948.	2.1	50
373	The Prevalence of Mood and Anxiety Disorders in Australian Women. <i>Australasian Psychiatry</i> , 2010, 18, 250-255.	0.9	50
374	Nutraceuticals in the treatment of Obsessive Compulsive Disorder (OCD): A review of mechanistic and clinical evidence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 887-895.	5.0	50
375	A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 564-568.	2.7	50
376	Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. <i>Translational Psychiatry</i> , 2015, 5, e495-e495.	4.9	50
377	The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders. <i>Molecular Neurobiology</i> , 2016, 53, 4638-4658.	4.1	50
378	Economic evaluation of a dietary intervention for adults with major depression (the "SMILES" trial). <i>BMC Public Health</i> , 2018, 18, 599.	3.0	50

#	ARTICLE	IF	CITATIONS
379	The case for improved care and provision of treatment for people with first-episode mania. <i>Lancet Psychiatry</i> , 2019, 6, 869-876.	7.6	50
380	Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin. <i>BMC Medicine</i> , 2020, 18, 16.	5.7	50
381	An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. <i>International Clinical Psychopharmacology</i> , 1997, 12, 137-140.	1.7	49
382	Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. <i>Bipolar Disorders</i> , 2012, 14, 1-21.	2.4	49
383	Tobacco Use in Bipolar Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 1-11.	2.1	49
384	Excessive daytime sleepiness and falls among older men and women: cross-sectional examination of a population-based sample. <i>BMC Geriatrics</i> , 2015, 15, 74.	2.8	49
385	Antioxidant treatments for schizophrenia. <i>The Cochrane Library</i> , 2016, 2016, CD008919.	2.8	49
386	Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial. <i>Clinical Psychopharmacology and Neuroscience</i> , 2014, 12, 180-188.	2.1	49
387	Lamotrigine and the treatment of mania in bipolar disorder. <i>European Neuropsychopharmacology</i> , 1999, 9, S119-S123.	1.6	48
388	A prospective study of the impact of smoking on outcomes in bipolar and schizoaffective disorder. <i>Comprehensive Psychiatry</i> , 2010, 51, 504-509.	3.3	48
389	A Comparison of Inflammatory Markers in Depressed and Nondepressed Smokers. <i>Nicotine and Tobacco Research</i> , 2012, 14, 540-546.	2.6	48
390	Stress, Inflammation, and Cellular Vulnerability during Early Stages of Affective Disorders: Biomarker Strategies and Opportunities for Prevention and Intervention. <i>Frontiers in Psychiatry</i> , 2014, 5, 34.	2.7	48
391	Optimizing delivery of recovery-oriented online self-management strategies for bipolar disorder: a review. <i>Bipolar Disorders</i> , 2015, 17, 115-127.	2.4	48
392	A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 241-249.	2.7	48
393	Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2019, 10, 605.	2.7	48
394	Socioeconomic Deprivation, Adverse Childhood Experiences and Medical Disorders in Adulthood: Mechanisms and Associations. <i>Molecular Neurobiology</i> , 2019, 56, 5866-5890.	4.1	48
395	Patterns of Association between Depressive Symptoms and Chronic Medical Morbidities in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1834-1841.	2.9	48
396	A Brain Capital Grand Strategy: toward economic reimagination. <i>Molecular Psychiatry</i> , 2021, 26, 3-22.	8.1	48

#	ARTICLE	IF	CITATIONS
397	Social isolation, social support and loneliness as independent concepts, and their relationship with health-related quality of life among older women. <i>Aging and Mental Health</i> , 2022, 26, 1335-1344.	2.8	48
398	The Putative Use of Lithium in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 853-861.	1.5	48
399	Effects of N-acetyl cysteine on cognitive function in bipolar disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2012, 66, 514-517.	2.2	47
400	Complementary medicine, self-help, and lifestyle interventions for Obsessive Compulsive Disorder (OCD) and the OCD spectrum: A systematic review. <i>Journal of Affective Disorders</i> , 2012, 138, 213-221.	4.2	47
401	Amygdala and insula volumes prior to illness onset in bipolar disorder: A magnetic resonance imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2012, 201, 34-39.	1.9	47
402	A comparison of schizophrenia, schizoaffective disorder, and bipolar disorder: Results from the Second Australian national psychosis survey. <i>Journal of Affective Disorders</i> , 2015, 172, 30-37.	4.2	47
403	In vivo hippocampal subfield volumes in bipolar disorder – A mega-analysis from The Enhancing Neuro Imaging Genetics through Meta-Analysis Bipolar Disorder Working Group. <i>Human Brain Mapping</i> , 2022, 43, 385-398.	3.7	47
404	Psychosocial Intervention With or Without Antipsychotic Medication for First-Episode Psychosis: A Randomized Noninferiority Clinical Trial. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	47
405	The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome. <i>Current Pharmaceutical Design</i> , 2016, 22, 6058-6075.	1.8	47
406	Do ambient electromagnetic fields affect behaviour? A demonstration of the relationship between geomagnetic storm activity and suicide. <i>Bioelectromagnetics</i> , 2006, 27, 151-155.	2.0	46
407	Neuroprotection in emerging psychotic disorders. <i>Microbial Biotechnology</i> , 2007, 1, 114-127.	1.9	46
408	The relationship between excessive daytime sleepiness and depressive and anxiety disorders in women. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 772-778.	2.7	46
409	The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2020, 276, 970-983.	4.2	46
410	The Management of Individuals with Bipolar Disorder. <i>Drugs</i> , 2009, 69, 2063-2101.	11.0	46
411	Superiority of Lithium Over Verapamil in Mania. <i>Journal of Clinical Psychiatry</i> , 1996, 57, 543-546.	2.3	46
412	Small shifts in diurnal rhythms are associated with an increase in suicide: The effect of daylight saving. <i>Sleep and Biological Rhythms</i> , 2008, 6, 22-25.	1.0	45
413	A neuro-immune, neuro-oxidative and neuro-nitrosative model of prenatal and postpartum depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 262-274.	5.0	45
414	Translational evidence for the Inflammatory Response System (IRS)/Compensatory Immune Response System (CIRS) and neuroprogression theory of major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110343.	5.0	45

#	ARTICLE	IF	CITATIONS
415	“Bipolar Mixed States”: The Diagnosis and Clinical Salience of Bipolar Mixed States. Australian and New Zealand Journal of Psychiatry, 2005, 39, 215-221.	2.7	44
416	Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disorders, 2009, 11, 55-76.	2.4	44
417	The association between depressive and anxiety symptoms and bone mineral density in the general population: The HUNT Study. Journal of Affective Disorders, 2011, 131, 164-171.	4.2	44
418	Biological underpinnings of the commonalities in depression, somatization, and Chronic Fatigue Syndrome. Medical Hypotheses, 2012, 78, 752-756.	1.5	44
419	The placebo effect: A clinicians guide. Australian and New Zealand Journal of Psychiatry, 2013, 47, 617-623.	2.7	44
420	Symptoms of Depression and Difficulty Initiating Sleep from Early Adolescence to Early Adulthood: A Longitudinal Study. Sleep, 2015, 38, 1599-1606.	1.1	44
421	Shortened telomere length in bipolar disorder: a comparison of the early and late stages of disease. Revista Brasileira De Psiquiatria, 2016, 38, 281-286.	2.7	44
422	Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?. Neuroscience and Biobehavioral Reviews, 2021, 120, 537-541.	6.6	44
423	Is this D Vitamin to Worry About? Vitamin D Insufficiency in an Inpatient Sample. Australian and New Zealand Journal of Psychiatry, 2008, 42, 874-878.	2.7	43
424	Pain and the relationship with mood and anxiety disorders and psychological symptoms. Journal of Psychosomatic Research, 2012, 72, 452-456.	2.8	43
425	Using lithium as a neuroprotective agent in patients with cancer. BMC Medicine, 2012, 10, 131.	5.7	43
426	Neurocognitive functioning in the prodrome of mania—an exploratory study. Journal of Affective Disorders, 2013, 147, 441-445.	4.2	43
427	Relationship between sunlight and the age of onset of bipolar disorder: An international multisite study. Journal of Affective Disorders, 2014, 167, 104-111.	4.2	43
428	Evolution of adolescent mental health in a rapidly changing socioeconomic environment: A review of mental health studies in adolescents in India over last 10 years. Asian Journal of Psychiatry, 2015, 13, 3-12.	2.1	43
429	Psychiatric disorders, psychotropic medication use and falls among women: an observational study. BMC Psychiatry, 2015, 15, 75.	2.6	43
430	Influence of light exposure during early life on the age of onset of bipolar disorder. Journal of Psychiatric Research, 2015, 64, 1-8.	3.2	43
431	The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: An integrative review of evidence, mechanisms, and clinical implications. Pharmacological Research, 2019, 139, 494-502.	7.1	43
432	Efficacy of Atypical Antipsychotics in Bipolar Disorder. Drugs, 2005, 65, 257-269.	11.0	42

#	ARTICLE	IF	CITATIONS
433	Development of guidelines for caregivers of people with bipolar disorder: a Delphi expert consensus study. <i>Bipolar Disorders</i> , 2011, 13, 556-570.	2.4	42
434	OxNASH Score Correlates with Histologic Features and Severity of Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1617-1624.	2.4	42
435	Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research. <i>Molecular Neurobiology</i> , 2016, 53, 2927-2935.	4.1	42
436	Variation in the prevalence of depression and patterns of association, sociodemographic and lifestyle factors in community-dwelling older adults in six low- and middle-income countries. <i>Journal of Affective Disorders</i> , 2019, 251, 218-226.	4.2	42
437	Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial. <i>Journal of Affective Disorders</i> , 2019, 245, 1007-1015.	4.2	42
438	Prebiotic and probiotic supplementation and the tryptophan-kynurenine pathway: A systematic review and meta analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 123, 1-13.	6.6	42
439	Nutritional ketosis as an intervention to relieve astrogliosis: Possible therapeutic applications in the treatment of neurodegenerative and neuroprogressive disorders. <i>European Psychiatry</i> , 2020, 63, e8.	0.2	42
440	The platelet intracellular calcium response to serotonin is augmented in bipolar manic and depressed patients. <i>Human Psychopharmacology</i> , 1995, 10, 189-193.	1.7	41
441	Emergency department mental health triage scales improve outcomes. <i>Journal of Evaluation in Clinical Practice</i> , 2004, 10, 57-62.	1.8	41
442	A Consensus Statement for Safety Monitoring Guidelines of Treatments for Major Depressive Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 712-725.	2.7	41
443	Impact of sunlight on the age of onset of bipolar disorder. <i>Bipolar Disorders</i> , 2012, 14, 654-663.	2.4	41
444	Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities. <i>Cell Chemical Biology</i> , 2017, 24, 825-832.e6.	5.2	41
445	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). <i>Journal of Affective Disorders</i> , 2022, 299, 367-376.	4.2	41
446	Improving competence in emergency mental health triage. <i>International Emergency Nursing</i> , 2002, 10, 155-162.	0.8	40
447	Antidepressant pharmacogenetics. <i>Current Opinion in Psychiatry</i> , 2014, 27, 43-51.	6.6	40
448	Predicting bipolar disorder on the basis of phenomenology: implications for prevention and early intervention. <i>Bipolar Disorders</i> , 2014, 16, 455-470.	2.4	40
449	Network Approaches to Understand Individual Differences in Brain Connectivity: Opportunities for Personality Neuroscience. <i>Personality Neuroscience</i> , 2018, 1, .	1.6	40
450	Effects of mindfulness-based stress reduction combined with music therapy on pain, anxiety, and sleep quality in patients with osteosarcoma. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 540-545.	2.7	40

#	ARTICLE	IF	CITATIONS
451	The impact of urbanization on mood disorders. <i>Current Opinion in Psychiatry</i> , 2019, 32, 198-203.	6.6	40
452	Measuring fatigue: a meta-review. <i>International Journal of Dermatology</i> , 2021, 60, 1053-1069.	1.0	40
453	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 483-494.	2.7	40
454	Preventing the development of severe COVID-19 by modifying immunothrombosis. <i>Life Sciences</i> , 2021, 264, 118617.	4.4	40
455	Inflammation and depression in young people: a systematic review and proposed inflammatory pathways. <i>Molecular Psychiatry</i> , 2022, 27, 315-327.	8.1	40
456	Pharmacological Treatment in the Early Phase of Bipolar Disorders: What Stage are we at?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 199-207.	2.7	39
457	Evaluation of the acceptability and usefulness of an information website for caregivers of people with bipolar disorder. <i>BMC Medicine</i> , 2013, 11, 162.	5.7	39
458	Depression, diet and exercise. <i>Medical Journal of Australia</i> , 2013, 199, S21-3.	1.7	39
459	Treatment Implications of Predominant Polarity and the Polarity Index: A Comprehensive Review. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu079-pyu079.	2.1	39
460	Nucleus accumbens deep-brain stimulation efficacy in ACTH-pretreated rats: alterations in mitochondrial function relate to antidepressant-like effects. <i>Translational Psychiatry</i> , 2016, 6, e842-e842.	4.9	39
461	Precision psychiatry with immunological and cognitive biomarkers: a multi-domain prediction for the diagnosis of bipolar disorder or schizophrenia using machine learning. <i>Translational Psychiatry</i> , 2020, 10, 162.	4.9	39
462	Obesity is associated with previous suicide attempts in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2010, 22, 63-67.	2.2	38
463	Is the safety of lithium no longer in the balance?. <i>Lancet, The</i> , 2012, 379, 690-692.	12.1	38
464	State-related alterations of gene expression in bipolar disorder: a systematic review. <i>Bipolar Disorders</i> , 2012, 14, 684-696.	2.4	38
465	Physical comorbidities in men with mood and anxiety disorders: a population-based study. <i>BMC Medicine</i> , 2013, 11, 110.	5.7	38
466	The effects of apoptosis vulnerability markers on the myocardium in depression after myocardial infarction. <i>BMC Medicine</i> , 2013, 11, 32.	5.7	38
467	Development of a Compact Rectenna for Wireless Powering of a Head-Mountable Deep Brain Stimulation Device. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2014, 2, 1-13.	3.9	38
468	How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 189-202.	2.7	38

#	ARTICLE	IF	CITATIONS
469	Longitudinal Structural Brain Changes in Bipolar Disorder: A Multicenter Neuroimaging Study of 1232 Individuals by the ENIGMA Bipolar Disorder Working Group. <i>Biological Psychiatry</i> , 2022, 91, 582-592.	1.3	38
470	Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review. <i>Journal of Affective Disorders</i> , 2021, 295, 740-751.	4.2	38
471	Serum levels of brain-derived neurotrophic factor in schizophrenia on a hypocaloric diet. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1595-1598.	5.0	37
472	Tobacco smoking predicts depression and poorer quality of life in heart disease. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 35.	1.7	37
473	N-acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats. <i>Metabolic Brain Disease</i> , 2013, 28, 687-696.	2.9	37
474	Internet use by patients with bipolar disorder: Results from an international multisite survey. <i>Psychiatry Research</i> , 2016, 242, 388-394.	3.4	37
475	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 330-348.	2.7	37
476	The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: A randomized placebo-controlled study. <i>Journal of Affective Disorders</i> , 2019, 245, 1043-1051.	4.2	37
477	The mental health and lifestyle impacts of COVID-19 on bipolar disorder. <i>Journal of Affective Disorders</i> , 2021, 282, 442-447.	4.2	37
478	The Impact of Smoking in Adolescence on Early Adult Anxiety Symptoms and the Relationship between Infant Vulnerability Factors for Anxiety and Early Adult Anxiety Symptoms: The TOPP Study. <i>PLoS ONE</i> , 2013, 8, e63252.	2.5	37
479	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. <i>Bipolar Disorders</i> , 2021, 23, 767-788.	2.4	37
480	Citalopram-associated clitoral priapism. <i>International Clinical Psychopharmacology</i> , 1997, 12, 121.	1.7	36
481	Anesthetic Induction for ECT with Etomidate Is Associated with Longer Seizure Duration Than Thiopentone. <i>Journal of ECT</i> , 1998, 14, 89-93.	0.7	36
482	Diagnosing bipolar disorder: how can we do it better?. <i>Medical Journal of Australia</i> , 2006, 184, 459-462.	1.7	36
483	Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: a nested, matched case-control study. <i>Bipolar Disorders</i> , 2010, 12, 253-263.	2.4	36
484	Assessing oxidative pathway genes as risk factors for bipolar disorder. <i>Bipolar Disorders</i> , 2010, 12, 550-556.	2.4	36
485	Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention. <i>Microbial Biotechnology</i> , 2011, 5, 100-107.	1.9	36
486	The use of hormonal contraceptive agents and mood disorders in women. <i>Journal of Affective Disorders</i> , 2012, 140, 92-96.	4.2	36

#	ARTICLE	IF	CITATIONS
487	Homocysteine as a peripheral biomarker in bipolar disorder: A meta-analysis. <i>European Psychiatry</i> , 2017, 43, 81-91.	0.2	36
488	Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 90, 212-220.	6.6	36
489	Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 681-697.	2.1	36
490	Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. <i>Microbial Biotechnology</i> , 2019, 13, 1032-1049.	1.9	36
491	Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study. <i>Diabetes Care</i> , 2020, 43, 3050-3060.	9.1	36
492	Blunted adenosine A2a receptor function in platelets in patients with major depression. <i>European Neuropsychopharmacology</i> , 2001, 11, 183-186.	1.6	35
493	Pharmacological management of unipolar depression. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 6-23.	4.5	35
494	Lovastatin for the adjunctive treatment of schizophrenia: A preliminary randomized double-blind placebo-controlled trial. <i>Psychiatry Research</i> , 2014, 219, 431-435.	3.4	35
495	Online information seeking by patients with bipolar disorder: results from an international multisite survey. <i>International Journal of Bipolar Disorders</i> , 2016, 4, 17.	2.2	35
496	N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms. <i>BMC Psychiatry</i> , 2016, 16, 320.	2.6	35
497	Defining melancholia: A core mood disorder. <i>Bipolar Disorders</i> , 2017, 19, 235-237.	2.4	35
498	Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer. <i>Cell Reports</i> , 2018, 22, 809-819.	6.3	35
499	Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions "Improvement (CGI-S) scale in bipolar and major depressive disorder. <i>European Psychiatry</i> , 2018, 53, 17-22.	0.2	35
500	A review of the neurobiological underpinning of comorbid substance use and mood disorders. <i>Journal of Affective Disorders</i> , 2018, 241, 388-401.	4.2	35
501	The role of high-density lipoprotein cholesterol, apolipoprotein A and paraoxonase-1 in the pathophysiology of neuroprogressive disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 125, 244-263.	6.6	35
502	Mitochondrial Dysfunction in the Pathophysiology of Bipolar Disorder: Effects of Pharmacotherapy. <i>Mini-Reviews in Medicinal Chemistry</i> , 2015, 15, 355-365.	2.6	35
503	The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders. <i>CNS Drugs</i> , 2022, 36, 451-482.	6.1	35
504	Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. <i>International Clinical Psychopharmacology</i> , 2001, 16, 275-278.	1.7	34

#	ARTICLE	IF	CITATIONS
505	Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. <i>Neuroscience Letters</i> , 2008, 433, 270-273.	2.1	34
506	Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18-month pilot study. <i>Microbial Biotechnology</i> , 2012, 6, 380-388.	1.9	34
507	Development of a measure quantifying adverse psychotherapeutic ingredients: The Experiences of Therapy Questionnaire (ETQ). <i>Psychiatry Research</i> , 2013, 206, 293-301.	3.4	34
508	Suicidal ideation and physical illness: Does the link lie with depression?. <i>Journal of Affective Disorders</i> , 2014, 152-154, 422-426.	4.2	34
509	Prospective progression from high-prevalence disorders to bipolar disorder: Exploring characteristics of pre-illness stages. <i>Journal of Affective Disorders</i> , 2015, 183, 45-48.	4.2	34
510	The use of statins for the treatment of depression in patients with acute coronary syndrome. <i>Translational Psychiatry</i> , 2015, 5, e620-e620.	4.9	34
511	Harnessing the potential of community-based participatory research approaches in bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2016, 4, 4.	2.2	34
512	The prevalence, age distribution and comorbidity of personality disorders in Australian women. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 141-150.	2.7	34
513	A randomized controlled trial of MoodSwings 2.0: An internet-based self-management program for bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 28-39.	2.4	34
514	Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities. <i>Pharmacological Research</i> , 2019, 148, 104450.	7.1	34
515	Does metabolic syndrome or its component factors alter the course of bipolar disorder? A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 142-153.	6.6	34
516	Effects of electroconvulsive therapy on regional cerebral blood flow measured by 99mtechnetium HMPAO SPECT. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 15-19.	5.0	33
517	Leptin in bipolar disorder: A systematic review and meta-analysis. <i>European Psychiatry</i> , 2016, 35, 1-7.	0.2	33
518	Beyond the therapeutic shackles of the monoamines: New mechanisms in bipolar disorder biology. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 72, 73-86.	5.0	33
519	Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels. <i>Behavioural Brain Research</i> , 2013, 242, 76-83.	2.3	32
520	Targeting the mitochondrial electron transport chain in autism, a systematic review and synthesis of a novel therapeutic approach. <i>Mitochondrion</i> , 2013, 13, 515-519.	3.5	32
521	Obesity and the relationship with positive and negative affect. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 477-482.	2.7	32
522	Age at onset, course of illness and response to psychotherapy in bipolar disorder: results from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). <i>Psychological Medicine</i> , 2014, 44, 3455-3467.	5.2	32

#	ARTICLE	IF	CITATIONS
523	Lithium and nephrotoxicity: Unravelling the complex pathophysiological threads of the lightest metal. <i>Nephrology</i> , 2018, 23, 897-903.	1.6	32
524	An immune gate of depression – Early neuroimmune development in the formation of the underlying depressive disorder. <i>Pharmacological Reports</i> , 2019, 71, 1299-1307.	3.3	32
525	Intracranial and subcortical volumes in adolescents with <scp>early-onset</scp> psychosis: A multisite <scp>mega-analysis</scp> from the <scp>ENIGMA</scp> consortium. <i>Human Brain Mapping</i> , 2022, 43, 373-384.	3.7	32
526	Induced Ketosis as a Treatment for Neuroprogressive Disorders: Food for Thought?. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 366-384.	2.1	32
527	Risk of cancer in bipolar disorder and the potential role of lithium: International collaborative systematic review and meta-analyses. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 126, 529-541.	6.6	32
528	Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. <i>Journal of the American College of Cardiology</i> , 1993, 22, A113-A118.	5.5	31
529	Should we be targeting smoking as a routine intervention?. <i>Acta Neuropsychiatrica</i> , 2007, 19, 131-132.	2.2	31
530	Differences between subjective and objective assessments of the utility of Electroconvulsive therapy in patients with bipolar and unipolar depression. <i>Journal of Affective Disorders</i> , 2009, 112, 212-218.	4.2	31
531	Preventive strategies in depression: gathering evidence for risk factors and potential interventions. <i>British Journal of Psychiatry</i> , 2012, 201, 339-341.	3.5	31
532	Alcohol consumption and body composition in a population-based sample of elderly Australian men. <i>Aging Clinical and Experimental Research</i> , 2013, 25, 183-192.	2.9	31
533	Development of an online intervention for bipolar disorder. www.moodswings.net.au . <i>Psychology, Health and Medicine</i> , 2013, 18, 155-165.	2.7	31
534	Autobiographical memory dysfunctions in depressive disorders. <i>Psychiatry and Clinical Neurosciences</i> , 2016, 70, 100-108.	2.2	31
535	Mitochondrial Agents for Bipolar Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 550-569.	2.1	31
536	Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 24-38.	2.7	31
537	Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging. <i>Journal of Biological Chemistry</i> , 2018, 293, 17829-17837.	3.5	31
538	Web-based intervention to improve quality of life in late stage bipolar disorder (ORBIT): randomised controlled trial protocol. <i>BMC Psychiatry</i> , 2018, 18, 221.	2.6	31
539	The interplay between oxidative stress and bioenergetic failure in neuropsychiatric illnesses: can we explain it and can we treat it?. <i>Molecular Biology Reports</i> , 2020, 47, 5587-5620.	2.4	31
540	The prevalence, odds and predictors of lifespan comorbid eating disorder among people with a primary diagnosis of bipolar disorders, and vice-versa: Systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2021, 280, 409-431.	4.2	31

#	ARTICLE	IF	CITATIONS
541	Supersensitive platelet glutamate receptors as a possible peripheral marker in schizophrenia. <i>International Clinical Psychopharmacology</i> , 1999, 14, 119-112.	1.7	30
542	Emerging Options in the Treatment of Bipolar Disorders. <i>Drugs</i> , 2001, 61, 1407-1414.	11.0	30
543	A Survey of Combination Antidepressant Use in Australia. <i>Australasian Psychiatry</i> , 2007, 15, 26-29.	0.9	30
544	The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. <i>Acta Neuropsychiatrica</i> , 2009, 21, 272-274.	2.2	30
545	Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 57, 69-75.	5.0	30
546	Functional Implications of the IL-23/IL-17 Immune Axis in Schizophrenia. <i>Molecular Neurobiology</i> , 2017, 54, 8170-8178.	4.1	30
547	Nutrition-based interventions for mood disorders. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 303-315.	2.8	30
548	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. <i>Bipolar Disorders</i> , 2021, 23, 659-678.	2.4	30
549	Inflammatory versus Anti-Inflammatory Profiles in Major Depressive Disordersâ€”The Role of IL-17, IL-21, IL-23, IL-35 and Foxp3. <i>Journal of Personalized Medicine</i> , 2021, 11, 66.	2.5	30
550	The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 289-303.	6.6	30
551	Zinc for treating of children and adolescents with attention-deficit hyperactivity disorder: a systematic review of randomized controlled clinical trials. <i>European Journal of Clinical Nutrition</i> , 2013, 67, 122-124.	2.8	29
552	Depression following fracture in women: a study of age-matched cohorts. <i>BMJ Open</i> , 2014, 4, e004226.	2.1	29
553	A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. <i>Psychoneuroendocrinology</i> , 2014, 43, 52-61.	2.8	29
554	Impact of comorbid anxiety disorders and obsessiveâ€”compulsive disorder on 24-month clinical outcomes of bipolar I disorder. <i>Journal of Affective Disorders</i> , 2014, 166, 243-248.	4.2	29
555	Factors influencing insulin resistance in relation to atherogenicity in mood disorders, the metabolic syndrome and tobacco use disorder. <i>Journal of Affective Disorders</i> , 2015, 179, 148-155.	4.2	29
556	Effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system in individuals at ultra-high risk of psychosis. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2015, 101, 15-21.	2.3	29
557	Efficacy of online lifestyle interventions targeting lifestyle behaviour change in depressed populations: A systematic review. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 834-846.	2.7	29
558	Adjunctive S-adenosylmethionine (SAME) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial., <i>European Neuropsychopharmacology</i> , 2018, 28, 1126-1136.	1.6	29

#	ARTICLE	IF	CITATIONS
559	Systemic inflammation and grey matter volume in schizophrenia and bipolar disorder: Moderation by childhood trauma severity. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 105, 110013.	5.0	29
560	Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis. <i>PLoS ONE</i> , 2016, 11, e0148429.	2.5	29
561	Qualitative Methods in Early-Phase Drug Trials. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 909-913.	2.3	29
562	Effects of Asenapine in Bipolar I Patients Meeting Proxy Criteria for Moderate-to-Severe Mixed Major Depressive Episodes. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 728-734.	2.3	29
563	A systematic review and meta-analysis of structural and functional brain alterations in individuals with genetic and clinical high-risk for psychosis and bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 117, 110540.	5.0	29
564	Clinical guidelines for the use of lifestyle-based mental health care in major depressive disorder: World Federation of Societies for Biological Psychiatry (WFSBP) and Australasian Society of Lifestyle Medicine (ASLM) taskforce. <i>World Journal of Biological Psychiatry</i> , 2023, 24, 333-386.	2.7	29
565	Predictors of antidepressant response: A selective review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2004, 8, 91-100.	2.7	28
566	Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. <i>Revista Brasileira De Psiquiatria</i> , 2008, 30, 337-340.	2.7	28
567	Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. <i>International Journal of Bipolar Disorders</i> , 2013, 1, 10.	2.2	28
568	Influence of birth cohort on age of onset cluster analysis in bipolar I disorder. <i>European Psychiatry</i> , 2015, 30, 99-105.	0.2	28
569	Oxidant/antioxidant imbalance is an inherent feature of depression. <i>BMC Psychiatry</i> , 2015, 15, 71.	2.6	28
570	The Putative Role of Viruses, Bacteria, and Chronic Fungal Biotoxin Exposure in the Genesis of Intractable Fatigue Accompanied by Cognitive and Physical Disability. <i>Molecular Neurobiology</i> , 2016, 53, 2550-2571.	4.1	28
571	Cognition in depression: Can we THINC-it better?. <i>Journal of Affective Disorders</i> , 2018, 225, 559-562.	4.2	28
572	The role of hypernitrosylation in the pathogenesis and pathophysiology of neuroprogressive diseases. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 84, 453-469.	6.6	28
573	Role of IL-6/RORC/IL-22 axis in driving Th17 pathway mediated immunopathogenesis of schizophrenia. <i>Cytokine</i> , 2018, 111, 112-118.	3.2	28
574	The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 775-783.	2.7	28
575	The role of microglia in neuroprogressive disorders: mechanisms and possible neurotherapeutic effects of induced ketosis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109858.	5.0	28
576	Nocebo Effects in the Treatment of Major Depression. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 702-711.	2.3	28

#	ARTICLE	IF	CITATIONS
577	H3K9 methylation drives resistance to androgen receptor antagonist therapy in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2114324119.	7.5	28
578	Quality of Life, Sexual Functioning and Sex Role Identity After Surgical Orchidectomy in Patients with Prostatic Cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 1995, 29, 497-500.	1.3	27
579	Changes in the platelet intracellular calcium response to serotonin in patients with major depression treated with electroconvulsive therapy: state or trait marker status. <i>International Clinical Psychopharmacology</i> , 2000, 15, 93-98.	1.7	27
580	Client-reported reasons for non-engagement in drug and alcohol treatment. <i>Drug and Alcohol Review</i> , 2009, 28, 372-378.	2.3	27
581	Venlafaxine modulates depression-induced behaviour and the expression of Bax mRNA and Bcl-xl mRNA in both hippocampus and myocardium. <i>Human Psychopharmacology</i> , 2011, 26, 95-101.	1.7	27
582	Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: an empirical cross-sectional study. <i>Revista Brasileira De Psiquiatria</i> , 2014, 36, 293-297.	2.7	27
583	Excessive daytime sleepiness and metabolic syndrome: a cross-sectional study. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 244-252.	3.6	27
584	Antimanic-like activity of candesartan in mice: Possible involvement of antioxidant, anti-inflammatory and neurotrophic mechanisms. <i>European Neuropsychopharmacology</i> , 2015, 25, 2086-2097.	1.6	27
585	Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology. <i>Current Molecular Medicine</i> , 2016, 16, 119-136.	1.3	27
586	SPECIFIC MOOD SYMPTOMS CONFER RISK FOR SUBSEQUENT SUICIDAL IDEATION IN BIPOLAR DISORDER WITH AND WITHOUT SUICIDE ATTEMPT HISTORY: MULTI-WAVE DATA FROM STEP-BD. <i>Depression and Anxiety</i> , 2016, 33, 464-472.	4.1	27
587	DNA methylation and the social gradient of osteoporotic fracture: A conceptual model. <i>Bone</i> , 2016, 84, 204-212.	3.0	27
588	Association between solar insolation and a history of suicide attempts in bipolar I disorder. <i>Journal of Psychiatric Research</i> , 2019, 113, 1-9.	3.2	27
589	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 2-16.	2.7	27
590	The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: a cross-sectional study. <i>Journal of Human Hypertension</i> , 2020, 34, 787-794.	2.2	27
591	The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. <i>Pharmacological Research</i> , 2021, 170, 105729.	7.1	27
592	The Human Phenotype Ontology in 2024: phenotypes around the world. <i>Nucleic Acids Research</i> , 2024, 52, D1333-D1346.	13.9	27
593	A Neuropsychological Study of Prefrontal Lobe Function in the Positive and Negative Subtypes of Schizophrenia. <i>Journal of Genetic Psychology</i> , 1997, 158, 487-494.	1.4	26
594	Barriers to treatment among members of a mental health advocacy group in South Africa. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2002, 37, 483-487.	3.3	26

#	ARTICLE	IF	CITATIONS
595	A prospective study of the impact of subthreshold mixed states on the 24-month clinical outcomes of bipolar I disorder or schizoaffective disorder. <i>Journal of Affective Disorders</i> , 2010, 124, 22-28.	4.2	26
596	Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 37, 132-135.	5.0	26
597	Emerging pharmacotherapy for cancer patients with cognitive dysfunction. <i>BMC Neurology</i> , 2013, 13, 153.	1.8	26
598	Evolution of optogenetic microdevices. <i>Neurophotonics</i> , 2015, 2, 031206.	3.4	26
599	A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up study. <i>European Psychiatry</i> , 2016, 31, 20-28.	0.2	26
600	Depression as a risk factor for fracture in women: A 10 year longitudinal study. <i>Journal of Affective Disorders</i> , 2016, 192, 34-40.	4.2	26
601	Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor. <i>Acta Neuropsychiatrica</i> , 2017, 29, 337-346.	2.2	26
602	Interactions between pro-inflammatory cytokines and statins on depression in patients with acute coronary syndrome. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 80, 250-254.	5.0	26
603	Stress, Depression, and Inflammation: Molecular and Microglial Mechanisms. <i>Biological Psychiatry</i> , 2018, 83, 5-6.	1.3	26
604	Diet and Depression—From Confirmation to Implementation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 842.	7.0	26
605	Impact of antipsychotic medication on IL-6/STAT3 signaling axis in peripheral blood mononuclear cells of drug-naïve schizophrenia patients. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 64-69.	2.2	26
606	Depression in the medically ill. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 346-366.	2.7	26
607	Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 1127-1133.	2.7	26
608	Predicting Risk of Suicide Attempt Using History of Physical Illnesses From Electronic Medical Records. <i>JMIR Mental Health</i> , 2016, 3, e19.	3.4	26
609	Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia. <i>Molecular Neurobiology</i> , 2022, 59, 3485-3503.	4.1	26
610	The evolution of clinical audit as a tool for quality improvement. <i>Journal of Evaluation in Clinical Practice</i> , 2003, 9, 251-257.	1.8	25
611	Atypical mood stabilizers: a 'typical' role for atypical antipsychotics. <i>Acta Psychiatrica Scandinavica</i> , 2005, 111, 29-38.	4.5	25
612	Restless Leg Syndrome Associated with Olanzapine: A Case Series. <i>Current Drug Safety</i> , 2010, 5, 129-131.	0.6	25

#	ARTICLE	IF	CITATIONS
613	The relationship between substance use and posttraumatic stress disorder in a methadone maintenance treatment program. <i>Comprehensive Psychiatry</i> , 2011, 52, 562-566.	3.3	25
614	The Efficacy and Safety of Alprazolam Versus Other Benzodiazepines in the Treatment of Panic Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 647-652.	1.4	25
615	Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial. <i>European Psychiatry</i> , 2015, 30, 975-982.	0.2	25
616	Citalopram and sertraline exposure compromises embryonic bone development. <i>Molecular Psychiatry</i> , 2016, 21, 656-664.	8.1	25
617	A potential role for N-acetylcysteine in the management of methamphetamine dependence. <i>Drug and Alcohol Review</i> , 2017, 36, 153-159.	2.3	25
618	A Comparison of Neuroimaging Abnormalities in Multiple Sclerosis, Major Depression and Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): is There a Common Cause?. <i>Molecular Neurobiology</i> , 2018, 55, 3592-3609.	4.1	25
619	<i>Garcinia mangostana</i> Linn displays antidepressant-like and pro-cognitive effects in a genetic animal model of depression: a bio-behavioral study in the Flinders Sensitive Line rat. <i>Metabolic Brain Disease</i> , 2018, 33, 467-480.	2.9	25
620	Buffering against maladaptive perfectionism in bipolar disorder: The role of self-compassion. <i>Journal of Affective Disorders</i> , 2019, 250, 132-139.	4.2	25
621	Changing dynamics of psychoneuroimmunology during the COVID-19 pandemic. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 5, 100096.	2.6	25
622	Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease: A Meta-Analysis of Mood Effects. <i>Neuropsychology Review</i> , 2021, 31, 385-401.	5.3	25
623	Dopamine increases platelet intracellular calcium in bipolar affective disorder and controls. <i>International Clinical Psychopharmacology</i> , 1994, 9, 291-294.	1.7	24
624	The therapeutic alliance: is it necessary or sufficient to engender positive outcomes?. <i>Acta Neuropsychiatrica</i> , 2009, 21, 95-98.	2.2	24
625	Pre-morbid and outcome correlates of first episode mania with psychosis: Is a distinction between schizoaffective and bipolar I disorder valid in the early phase of psychotic disorders?. <i>Journal of Affective Disorders</i> , 2010, 126, 88-95.	4.2	24
626	The role of alprazolam for the treatment of panic disorder in Australia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 212-224.	2.7	24
627	Co-morbid cardiovascular disease and depression: sequence of disease onset is linked to mental but not physical self-rated health. Results from a cross-sectional, population-based study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2012, 47, 1145-1151.	3.3	24
628	Relationship between membrane fatty acids and cognitive symptoms and information processing in individuals at ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2014, 158, 39-44.	2.0	24
629	Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study. <i>PLoS ONE</i> , 2016, 11, e0151417.	2.5	24
630	Affective instability and the course of bipolar depression: Results from the STEP-BD randomised controlled trial of psychosocial treatment. <i>British Journal of Psychiatry</i> , 2016, 208, 352-358.	3.5	24

#	ARTICLE	IF	CITATIONS
631	Endurance Exercise and the Heart: Friend or Foe?. <i>Sports Medicine</i> , 2016, 46, 459-466.	6.6	24
632	Antimicrobial resistance, penicillin-binding protein sequences, and pilus islet carriage in relation to clonal evolution of <i>Streptococcus pneumoniae</i> serotype 19A in Russia, 2002–2013. <i>Epidemiology and Infection</i> , 2017, 145, 1708-1719.	2.1	24
633	Defining disorders with permeable borders: you say bipolar, I say borderline!. <i>Bipolar Disorders</i> , 2017, 19, 320-323.	2.4	24
634	Solar insolation in springtime influences age of onset of bipolar I disorder. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 571-582.	4.5	24
635	Can Depression Be Prevented? If So, How?. <i>JAMA Psychiatry</i> , 2020, 77, 1095.	11.3	24
636	Cocaine-Induced Changes in Tonic Dopamine Concentrations Measured Using Multiple-Cyclic Square Wave Voltammetry in vivo. <i>Frontiers in Pharmacology</i> , 2021, 12, 705254.	3.6	24
637	Lithium therapy and weight change in people with bipolar disorder: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 134, 104266.	6.6	24
638	A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. <i>International Clinical Psychopharmacology</i> , 1999, 14, 177-180.	1.7	23
639	A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder. <i>International Clinical Psychopharmacology</i> , 1999, 14, 177-180.	1.7	23
640	Platelet Supersensitivity to Thrombin Stimulation in Depression: A Possible Mechanism for the Association with Cardiovascular Mortality. <i>Clinical Neuropharmacology</i> , 2000, 23, 182-185.	0.7	23
641	Pilot of group intervention for bipolar disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007, 11, 279-284.	2.7	23
642	Oxidative stress may be a common mechanism linking major depression and osteoporosis. <i>Acta Neuropsychiatrica</i> , 2008, 20, 112-116.	2.2	23
643	Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking <i>N</i> -acetyl-cysteine versus placebo. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 347-354.	2.7	23
644	Socio-demographic, lifestyle and psychological predictors of benzodiazepine and z-hypnotic use patterns. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 107-116.	1.5	23
645	Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder. <i>Psychiatry Investigation</i> , 2015, 12, 349.	1.6	23
646	Physical health comorbidities in women with personality disorder: Data from the Geelong Osteoporosis Study. <i>European Psychiatry</i> , 2016, 34, 29-35.	0.2	23
647	Association between childhood trauma exposure and pro-inflammatory cytokines in schizophrenia and bipolar-I disorder. <i>Psychological Medicine</i> , 2019, 49, 2736-2744.	5.2	23
648	Relationships Between Different Dimensions of Social Support and Suicidal Ideation in Young People with Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2021, 281, 714-720.	4.2	23

#	ARTICLE	IF	CITATIONS
649	A proof-of-concept study of maternal immune activation mediated induction of Toll-like receptor (TLR) and inflammasome pathways leading to neuroprogressive changes and schizophrenia-like behaviours in offspring. <i>European Neuropsychopharmacology</i> , 2021, 52, 48-61.	1.6	23
650	Treatment of bipolar mania with atypical antipsychotics. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, S17-S25.	2.8	22
651	The relationship between depression and cardiovascular disease. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005, 9, 157-167.	2.7	22
652	Decreased serum neurotrophin 3 in chronically medicated schizophrenic males. <i>Neuroscience Letters</i> , 2008, 440, 197-201.	2.1	22
653	The impact of age at onset of bipolar I disorder on functioning and clinical presentation. <i>Acta Neuropsychiatrica</i> , 2009, 21, 191-196.	2.2	22
654	Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia. <i>Medical Gas Research</i> , 2013, 3, 11.	2.4	22
655	Extreme attributions predict transition from depression to mania or hypomania in bipolar disorder. <i>Journal of Psychiatric Research</i> , 2013, 47, 1329-1336.	3.2	22
656	Extreme Attributions Predict the Course of Bipolar Depression. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 249-255.	2.3	22
657	Statin and Aspirin Use and the Risk of Mood Disorders among Men. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw008.	2.1	22
658	Do Statins Have Antidepressant Effects?. <i>CNS Drugs</i> , 2017, 31, 335-343.	6.1	22
659	Promotion of Wellbeing for Children of Parents With Mental Illness: A Model Protocol for Research and Intervention. <i>Frontiers in Psychiatry</i> , 2019, 10, 606.	2.7	22
660	Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d'essais randomisés contrôlés. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 849-862.	2.2	22
661	Trends in 30-day readmissions following hospitalisation for heart failure by sex, socioeconomic status and ethnicity. <i>EClinicalMedicine</i> , 2021, 38, 101008.	7.1	22
662	Predictors of functional impairment in bipolar disorder: Results from 13 cohorts from seven countries by the global bipolar cohort collaborative. <i>Bipolar Disorders</i> , 2022, 24, 709-719.	2.4	22
663	The effect of different degrees of lockdown and self-identified gender on anxiety, depression and suicidality during the COVID-19 pandemic: Data from the international COMET-G study.. <i>Psychiatry Research</i> , 2022, 315, 114702.	3.4	22
664	Clotiapine for acute psychotic illnesses. <i>The Cochrane Library</i> , 2004, , CD002304.	2.8	21
665	Acute Delirium in the Setting of Primary Hypothyroidism: The Role of Thyroid Hormone Replacement Therapy. <i>Thyroid</i> , 2005, 15, 1099-1101.	4.9	21
666	Paracetamol (acetaminophen) use, fracture and bone mineral density. <i>Bone</i> , 2011, 48, 1277-1281.	3.0	21

#	ARTICLE	IF	CITATIONS
667	A Low Power Micro Deep Brain Stimulation Device for Murine Preclinical Research. IEEE Journal of Translational Engineering in Health and Medicine, 2013, 1, 1500109-1500109.	3.9	21
668	Homocysteine as a potential biomarker in bipolar disorders: a critical review and suggestions for improved studies. Expert Opinion on Therapeutic Targets, 2015, 19, 927-939.	3.4	21
669	Distinguishing transient versus stable aspects of depression in New Zealand Pacific Island children using Generalizability Theory. Journal of Affective Disorders, 2018, 227, 698-704.	4.2	21
670	The MHC/HLA Gene Complex in Major Psychiatric Disorders: Emerging Roles and Implications. Current Behavioral Neuroscience Reports, 2018, 5, 179-188.	1.4	21
671	Beyond evidence-based treatment of bipolar disorder: Rational pragmatic approaches to management. Bipolar Disorders, 2019, 21, 650-659.	2.4	21
672	The compensatory antioxidant response system with a focus on neuroprogressive disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 95, 109708.	5.0	21
673	Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity – a consensus of the Biomarkers Task Force from the WFSBP. World Journal of Biological Psychiatry, 2019, 20, 340-351.	2.7	21
674	New drug candidates for bipolar disorder – A nation-wide population-based study. Bipolar Disorders, 2019, 21, 410-418.	2.4	21
675	The role of depression pharmacogenetic decision support tools in shared decision making. Journal of Neural Transmission, 2019, 126, 87-94.	2.9	21
676	EPA and DHA as markers of nutraceutical treatment response in major depressive disorder. European Journal of Nutrition, 2020, 59, 2439-2447.	4.0	21
677	Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. Science Translational Medicine, 2021, 13, .	13.3	21
678	Polyphenols as adjunctive treatments in psychiatric and neurodegenerative disorders: Efficacy, mechanisms of action, and factors influencing inter-individual response. Free Radical Biology and Medicine, 2021, 172, 101-122.	4.5	21
679	Excessive Daytime Sleepiness and Body Composition: A Population-Based Study of Adults. PLoS ONE, 2014, 9, e112238.	2.5	21
680	Into the Bowels of Depression: Unravelling Medical Symptoms Associated with Depression by Applying Machine-Learning Techniques to a Community Based Population Sample. PLoS ONE, 2016, 11, e0167055.	2.5	21
681	Universal depression prevention: An umbrella review of meta-analyses. Journal of Psychiatric Research, 2021, 144, 483-493.	3.2	21
682	Efficacy of low carbohydrate and ketogenic diets in treating mood and anxiety disorders: systematic review and implications for clinical practice. BJPsych Open, 2023, 9, .	0.7	21
683	The pharmacology of bipolar disorder during pregnancy and breastfeeding. Expert Opinion on Drug Safety, 2004, 3, 221-229.	2.5	20
684	Self-Reported Depression and Cardiovascular Risk Factors in a Community Sample of Women. Psychosomatics, 2007, 48, 54-59.	2.5	20

#	ARTICLE	IF	CITATIONS
685	Dual Action? Combining Venlafaxine and Mirtazapine in the Treatment of Depression. Australian and New Zealand Journal of Psychiatry, 2008, 42, 346-349.	2.7	20
686	Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. Expert Review of Neurotherapeutics, 2008, 8, 1299-1306.	2.8	20
687	Translating the Rosetta Stone of N-Acetylcysteine. Biological Psychiatry, 2012, 71, 935-936.	1.3	20
688	Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice. BMC Psychiatry, 2012, 12, 228.	2.6	20
689	Cannabinoid receptors on peripheral leukocytes from patients with schizophrenia: Evidence for defective immunomodulatory mechanisms. Journal of Psychiatric Research, 2017, 87, 44-52.	3.2	20
690	Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. Annals of Oncology, 2020, 31, 369-376.	1.3	20
691	Neurovegetative symptom subtypes in young people with major depressive disorder and their structural brain correlates. Translational Psychiatry, 2020, 10, 108.	4.9	20
692	Moclobemide Twice Daily in the Treatment of Major Depressive Episode. Journal of Clinical Psychopharmacology, 1995, 15, 4S-9S.	1.4	20
693	The Australian Genetics of Depression Study: New Risk Loci and Dissecting Heterogeneity Between Subtypes. Biological Psychiatry, 2022, 92, 227-235.	1.3	20
694	A randomized controlled single blind study of the efficacy of clonazepam and lithium in the treatment of acute mania. Human Psychopharmacology, 1997, 12, 325-328.	1.7	19
695	Mood Stabilizers and Treatment Adherence in Bipolar Disorder: Addressing Adverse Events. Annals of Clinical Psychiatry, 2003, 15, 217-224.	1.5	19
696	Pharmacological management of aggression and violence. Human Psychopharmacology, 2003, 18, 423-436.	1.7	19
697	Psychosocial interventions for bipolar disorder. Acta Neuropsychiatrica, 2009, 21, 275-284.	2.2	19
698	Gender differences in first episode psychotic mania. BMC Psychiatry, 2013, 13, 82.	2.6	19
699	Treatment response for acute depression is not associated with number of previous episodes: Lack of evidence for a clinical staging model for major depressive disorder. Journal of Affective Disorders, 2013, 150, 344-349.	4.2	19
700	Differences between first episode schizophrenia and schizoaffective disorder. Schizophrenia Research, 2013, 147, 169-174.	2.0	19
701	Why so GLUMM? Detecting depression clusters through graphing lifestyle-environs using machine-learning methods (GLUMM). European Psychiatry, 2017, 39, 40-50.	0.2	19
702	Mechanisms Underpinning the Polypharmacy Effects of Medications in Psychiatry. International Journal of Neuropsychopharmacology, 2018, 21, 582-591.	2.1	19

#	ARTICLE	IF	CITATIONS
703	Supporting Engagement, Adherence, and Behavior Change in Online Dietary Interventions. <i>Journal of Nutrition Education and Behavior</i> , 2019, 51, 719-739.	0.7	19
704	Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low risk of self-harm or aggression. Study protocol and baseline characteristics of participants. <i>Microbial Biotechnology</i> , 2019, 13, 953-960.	1.9	19
705	S-Adenosylmethionine (SAME) monotherapy for depression: an 8-week double-blind, randomised, controlled trial. <i>Psychopharmacology</i> , 2020, 237, 209-218.	3.1	19
706	Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis. <i>JAMA Network Open</i> , 2020, 3, e2024335.	6.0	19
707	Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial. <i>Molecular Psychiatry</i> , 2021, 26, 5161-5170.	8.1	19
708	Nutrition and bipolar disorder: a systematic review. <i>Nutritional Neuroscience</i> , 2023, 26, 637-651.	3.0	19
709	The prolactin response to sulpiride in major depression: the role of the D2 receptor in depression. <i>European Neuropsychopharmacology</i> , 2001, 11, 215-220.	1.6	18
710	Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial. <i>Human Psychopharmacology</i> , 2003, 18, 271-275.	1.7	18
711	The Safety of Medications for the Treatment of Bipolar Disorder During Pregnancy and the Puerperium. <i>Current Drug Safety</i> , 2006, 1, 25-33.	0.6	18
712	Gastro oesophageal reflux disease (GORD)-related symptoms and its association with mood and anxiety disorders and psychological symptomology: a population-based study in women. <i>BMC Psychiatry</i> , 2013, 13, 194.	2.6	18
713	Genetic polymorphisms in glutathione-S-transferases are associated with anxiety and mood disorders in nicotine dependence. <i>Psychiatric Genetics</i> , 2014, 24, 87-93.	1.1	18
714	Three Paths to Drug Discovery in Psychiatry. <i>American Journal of Psychiatry</i> , 2015, 172, 412-414.	8.6	18
715	Personality disorder and population mental health. <i>Lancet Psychiatry</i> , 2015, 2, 201-202.	7.6	18
716	Perimetry, Retinal Nerve Fiber Layer Thickness and Papilledema Grade After Cerebrospinal Fluid Shunting in Patients With Idiopathic Intracranial Hypertension. <i>Journal of Neuro-Ophthalmology</i> , 2015, 35, 22-25.	0.8	18
717	ASPREE-D: Aspirin for the prevention of depression in the elderly. <i>International Psychogeriatrics</i> , 2016, 28, 1741-1748.	1.1	18
718	Impact of irritability: a 2-year observational study of outpatients with bipolar I or schizoaffective disorder. <i>Bipolar Disorders</i> , 2017, 19, 184-197.	2.4	18
719	Mixed mood: The not so united states?. <i>Bipolar Disorders</i> , 2017, 19, 242-245.	2.4	18
720	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1173-1182.	2.7	18

#	ARTICLE	IF	CITATIONS
721	Unravelling facets of milk derived opioid peptides: a focus on gut physiology, fractures and obesity. <i>International Journal of Food Sciences and Nutrition</i> , 2020, 71, 36-49.	2.7	18
722	Genetics of methamphetamine use disorder: A systematic review and meta-analyses of gene association studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 48-74.	6.6	18
723	Restless Leg Syndrome Associated with Atypical Antipsychotics: Current Status, Pathophysiology, and Clinical Implications. <i>Current Drug Safety</i> , 2015, 10, 98-105.	0.6	18
724	Plasma Levels of Tumor Necrosis Factor Superfamily Molecules Are Increased in Bipolar Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2017, 15, 269-275.	2.1	18
725	A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. <i>Human Psychopharmacology</i> , 1998, 13, 17-20.	1.7	17
726	Cognitive-Personality Style as Vulnerability to Depression in Patients With Coronary Artery Disease: Roles of Sociotropy and Autonomy. <i>Psychosomatic Medicine</i> , 2009, 71, 63-69.	2.1	17
727	Area-based socioeconomic status and mood disorders: Cross-sectional evidence from a cohort of randomly selected adult women. <i>Maturitas</i> , 2011, 69, 173-178.	2.5	17
728	Pathways to new drug discovery in neuropsychiatry. <i>BMC Medicine</i> , 2012, 10, 151.	5.7	17
729	Quantitative Heel Ultrasound (QUS) measures of bone quality in association with mood and anxiety disorders. <i>Journal of Affective Disorders</i> , 2013, 146, 395-400.	4.2	17
730	Diagnosing bipolar disorder: Defining thresholds and setting boundaries. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 500-504.	2.7	17
731	Validation of a Portable Low-Power Deep Brain Stimulation Device Through Anxiolytic Effects in a Laboratory Rat Model. <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2017, 25, 1365-1374.	5.0	17
732	Selective Serotonin Reuptake Inhibitors (SSRIs) and Markers of Bone Turnover in Men. <i>Calcified Tissue International</i> , 2018, 103, 125-130.	3.1	17
733	Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 784-798.	2.7	17
734	Single-Nucleotide Polymorphisms of Genes Involved in Repair of Oxidative DNA Damage and the Risk of Recurrent Depressive Disorder. <i>Medical Science Monitor</i> , 2016, 22, 4455-4474.	1.1	17
735	Nasal Continuous Positive Airway Pressure Inhibits Gastroesophageal Reflux in Newborn Lambs. <i>PLoS ONE</i> , 2014, 9, e107736.	2.5	17
736	Deep Brain Stimulation for Addictive Disorders—Where Are We Now?. <i>Neurotherapeutics</i> , 2022, 19, 1193-1215.	4.7	17
737	Alloxan-induced diabetes mellitus in the pregnant ewe: Metabolic and cardiovascular effects on the mother and her fetus. <i>American Journal of Obstetrics and Gynecology</i> , 1989, 160, 1239-1244.	1.3	16
738	Lithium Blocks 45Ca^{2+} Uptake into Platelets in Bipolar Affective Disorder and Controls. <i>Clinical Neuropharmacology</i> , 1996, 19, 48-51.	0.7	16

#	ARTICLE	IF	CITATIONS
739	Augmented platelet calcium uptake in response to serotonin stimulation in patients with major depression measured using Mn ²⁺ influx and ⁴⁵ Ca ²⁺ uptake. <i>Life Sciences</i> , 1999, 66, 425-431.	4.4	16
740	Value and effectiveness of consumer advocacy groups: A survey of the anxiety disorders support group in South Africa. <i>Depression and Anxiety</i> , 2001, 13, 105-107.	4.1	16
741	A pilot randomized, double-blind, placebo-controlled study of granisetron in the treatment of sexual dysfunction in women associated with antidepressant use. <i>International Clinical Psychopharmacology</i> , 2004, 19, 161-164.	1.7	16
742	Co-prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population-based study with focus on gender differences. <i>BMC Medicine</i> , 2012, 10, 148.	5.7	16
743	The sick role, illness cognitions and outcomes in bipolar disorder. <i>Journal of Affective Disorders</i> , 2013, 146, 146-149.	4.2	16
744	Quality of life in bipolar and schizoaffective disorder – A naturalistic approach. <i>Comprehensive Psychiatry</i> , 2014, 55, 1540-1545.	3.3	16
745	Application of the Gradient Boosted method in randomised clinical trials: Participant variables that contribute to depression treatment efficacy of duloxetine, SSRIs or placebo. <i>Journal of Affective Disorders</i> , 2014, 168, 284-293.	4.2	16
746	Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness. <i>Psychiatry Research</i> , 2015, 226, 368-375.	3.4	16
747	An adjunctive antidepressant nutraceutical combination in treating major depression: Study protocol, and clinical considerations. <i>Advances in Integrative Medicine</i> , 2015, 2, 49-55.	1.0	16
748	Youth depression alleviation: the Fish Oil Youth Depression Study (<sc>YoDA</sc>): A randomized, double-blind, placebo-controlled treatment trial. <i>Microbial Biotechnology</i> , 2016, 10, 290-299.	1.9	16
749	The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 395.	1.6	16
750	Medical burden, body mass index and the outcome of psychosocial interventions for bipolar depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 667-677.	2.7	16
751	Online ethics: where will the interface of mental health and the internet lead us?. <i>International Journal of Bipolar Disorders</i> , 2017, 5, 26.	2.2	16
752	Youth Depression Alleviation – Augmentation with an anti-inflammatory agent (<sc>YoDA</sc>): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin. <i>Microbial Biotechnology</i> , 2018, 12, 45-54.	1.9	16
753	AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation. <i>Endocrinology</i> , 2018, 159, 2884-2890.	2.8	16
754	Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression. <i>Acta Neuropsychiatrica</i> , 2018, 30, 334-341.	2.2	16
755	The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, 115.	2.7	16
756	Drugs used to treat bipolar disorder act via microRNAs to regulate expression of genes involved in neurite outgrowth. <i>Journal of Psychopharmacology</i> , 2020, 34, 370-379.	4.2	16

#	ARTICLE	IF	CITATIONS
757	Statins: Neurobiological underpinnings and mechanisms in mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 693-708.	6.6	16
758	Safe and effective use of lithium. <i>Australian Prescriber</i> , 2013, 36, 18-21.	1.0	16
759	Prevalence of Cardiovascular and Metabolic Events in Patients Prescribed Clozapine: A Retrospective Observational, Clinical Cohort Study. <i>Current Drug Safety</i> , 2015, 10, 125-131.	0.6	16
760	Hyponatraemia: An Audit of Aged Psychiatry Patients Taking SSRIs and SNRIs. <i>Current Drug Safety</i> , 2013, 8, 175-180.	0.6	16
761	Strategies and foundations for scientific discovery in longitudinal studies of bipolar disorder. <i>Bipolar Disorders</i> , 2022, 24, 499-508.	2.4	16
762	Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis. <i>JAMA Network Open</i> , 2021, 4, e2140858.	6.0	16
763	Effect of mitral regurgitation and volume loading on pressure half-time before and after balloon valvotomy in mitral stenosis. <i>American Journal of Cardiology</i> , 1991, 67, 162-168.	1.6	15
764	Paroxetine induced withdrawal effects. <i>Human Psychopharmacology</i> , 1995, 10, 147-148.	1.7	15
765	Antidepressant induced mania in obsessive compulsive disorder. <i>European Neuropsychopharmacology</i> , 1996, 6, 9-11.	1.6	15
766	Season of Birth and Schizophrenia: Southern Hemisphere Data. <i>Australian and New Zealand Journal of Psychiatry</i> , 1996, 30, 220-222.	2.7	15
767	Auto-amputation of the tongue associated with flupenthixol induced extrapyramidal symptoms. <i>International Clinical Psychopharmacology</i> , 1999, 14, 129-131.	1.7	15
768	Serotonergic targets in the treatment of antidepressant induced sexual dysfunction: a pilot study of granisetron and sumatriptan. <i>International Clinical Psychopharmacology</i> , 2000, 15, 291-295.	1.7	15
769	Personality factors, stress and immunity. <i>Stress and Health</i> , 2001, 17, 25-40.	2.7	15
770	A Clinical Monitoring System for Clozapine. <i>Australasian Psychiatry</i> , 2006, 14, 156-168.	0.9	15
771	Should we be targeting exercise as a routine mental health intervention?. <i>Acta Neuropsychiatrica</i> , 2007, 19, 217-218.	2.2	15
772	Net-effect? Online psychological interventions. <i>Acta Neuropsychiatrica</i> , 2007, 19, 386-388.	2.2	15
773	Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 97, 293-300.	2.8	15
774	Patterns of Alcohol Use and Associated Physical and Lifestyle Characteristics According to New Australian Guidelines. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 946-951.	2.7	15

#	ARTICLE	IF	CITATIONS
775	Are we missing opportunities for early intervention in bipolar disorder?. Expert Review of Neurotherapeutics, 2012, 12, 5-7.	2.8	15
776	The DSM-5: Hyperbole, Hope or Hypothesis?. BMC Medicine, 2013, 11, 128.	5.7	15
777	Attributions of responsibility and recovery within a no-fault insurance compensation system.. Rehabilitation Psychology, 2014, 59, 247-255.	1.2	15
778	The impact of HLA-G 3' UTR variants and sHLA-G on risk and clinical correlates of schizophrenia. Human Immunology, 2016, 77, 1166-1171.	2.6	15
779	IFR4/MUM1-positive lymphoma in Waldeyer ring with co-expression of CD5 and CD10. Pediatric Blood and Cancer, 2017, 64, 311-314.	1.6	15
780	Early intervention for bipolar disorder – Do current treatment guidelines provide recommendations for the early stages of the disorder?. Journal of Affective Disorders, 2019, 257, 669-677.	4.2	15
781	Biomarker-Guided Anti-inflammatory Therapies. JAMA Psychiatry, 2019, 76, 779.	11.3	15
782	Are remitted affective disorders and familial risk of affective disorders associated with metabolic syndrome, inflammation and oxidative stress? – a monozygotic twin study. Psychological Medicine, 2020, 50, 1736-1745.	5.2	15
783	Psychosocial interventions for self-harm in low-income and middle-income countries: systematic review and theory of change. Social Psychiatry and Psychiatric Epidemiology, 2021, 56, 1729-1750.	3.3	15
784	N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial. EClinicalMedicine, 2021, 38, 101005.	7.1	15
785	Staging in bipolar disorder: one step closer to precision psychiatry. Revista Brasileira De Psiquiatria, 2017, 39, 88-89.	2.7	15
786	Child and Parent Physical Activity, Sleep, and Screen Time During COVID-19 and Associations With Mental Health: Implications for Future Psycho-Cardiological Disease?. Frontiers in Psychiatry, 2021, 12, 774858.	2.7	15
787	Chronic Idiopathic Hypertrophic Osteoarthropathy. New England Journal of Medicine, 1952, 247, 123-126.	29.7	14
788	LEFT VENTRICULAR ANEURYSM IN A BANTU CHILD. Heart, 1964, 26, 859-861.	3.8	14
789	The augmented platelet intracellular calcium response to serotonin in anorexia nervosa but not bulimia may be due to subsyndromal depression. International Journal of Eating Disorders, 1997, 22, 57-63.	4.6	14
790	Clusters of personality traits and psychological symptoms associated with later benzodiazepine prescriptions in the general population: The HUNT Cohort Study. Addictive Behaviors, 2013, 38, 2575-2580.	3.2	14
791	Data Integration Protocol In Ten-steps (DIPIT): A new standard for medical researchers. Methods, 2014, 69, 237-246.	3.9	14
792	Association of paraoxonase (PON)1 activity, glutathione S-transferase GST T1/M1 and STin.2 polymorphisms with comorbidity of tobacco use disorder and mood disorders. Neuroscience Letters, 2015, 585, 132-137.	2.1	14

#	ARTICLE	IF	CITATIONS
793	The association between attributions of responsibility for motor vehicle accidents and patient satisfaction: a study within a no-fault injury compensation system. <i>Clinical Rehabilitation</i> , 2015, 29, 500-508.	2.4	14
794	Instruments that prospectively predict bipolar disorder – A systematic review. <i>Journal of Affective Disorders</i> , 2015, 179, 65-73.	4.2	14
795	The trajectory of cognitive functioning following first episode mania: A 12-month follow-up study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 1186-1197.	2.7	14
796	Ethical considerations in preventive interventions for bipolar disorder. <i>Microbial Biotechnology</i> , 2017, 11, 104-112.	1.9	14
797	Gender differences in quality of life and functional disability for depression outpatients with or without residual symptoms after acute phase treatment in China. <i>Journal of Affective Disorders</i> , 2017, 219, 141-148.	4.2	14
798	Influence of maturity degree, modified atmosphere and anti-browning dipping on texture changes kinetics of fresh-cut apples. <i>Postharvest Biology and Technology</i> , 2017, 124, 137-146.	6.0	14
799	Internet use by older adults with bipolar disorder: international survey results. <i>International Journal of Bipolar Disorders</i> , 2018, 6, 20.	2.2	14
800	A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine (dependence). <i>Trials</i> , 2019, 20, 325.	1.6	14
801	Childbirth and prevention of bipolar disorder: an opportunity for change. <i>Lancet Psychiatry</i> , 2019, 6, 786-792.	7.6	14
802	Development of a miniature device for emerging deep brain stimulation paradigms. <i>PLoS ONE</i> , 2019, 14, e0212554.	2.5	14
803	Depression, stress and vascular function from childhood to adolescence: A longitudinal investigation. <i>General Hospital Psychiatry</i> , 2020, 62, 6-12.	2.5	14
804	Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive N-acetylcysteine and mitochondrial agents in adults with bipolar disorder: A sub-study of a randomised placebo-controlled trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 159-172.	2.7	14
805	The effects of childhood emotional maltreatment and alexithymia on depressive and manic symptoms and suicidal ideation in females with bipolar disorder: emotion dysregulation as a mediator. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 90-102.	2.7	14
806	Optimizing Engagement in an Online Dietary Intervention for Depression (My Food & Mood Version) <i>Tj ETQq0,0,0 rgBT /Qverlock 1</i>	3.4	14
807	Disruption of circadian rhythm and risk of autism spectrum disorder: role of immune-inflammatory, oxidative stress, metabolic and neurotransmitter pathways. <i>Reviews in the Neurosciences</i> , 2022, 33, 93-109.	3.2	14
808	Cognition-immune interactions between executive function and working memory, tumour necrosis factor-alpha (TNF-alpha) and soluble TNF receptors (sTNFR1 and sTNFR2) in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 67-77.	2.7	14
809	Transcriptional Modulation of the Hippo Signaling Pathway by Drugs Used to Treat Bipolar Disorder and Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7164.	4.2	14
810	A study of the transition metal doped boron nitride nanosheets as promising candidates for hydrogen and formaldehyde adsorptions. <i>Physica E: Low-Dimensional Systems and Nanostructures</i> , 2021, 134, 114859.	2.8	14

#	ARTICLE	IF	CITATIONS
811	Lithium therapy and its interactions. Australian Prescriber, 2020, 43, 91-93.	1.0	14
812	Cocaine increases stimulation-evoked serotonin efflux in the nucleus accumbens. Journal of Neurophysiology, 2022, 127, 714-724.	1.9	14
813	Trajectories of depressive symptoms in older adults and associated health outcomes. Nature Aging, 2022, 2, 295-302.	8.4	14
814	Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial. Acta Neuropsychiatrica, 2009, 21, 285-291.	2.2	13
815	Mania: Diagnosis and Treatment Recommendations. Current Psychiatry Reports, 2012, 14, 676-686.	4.5	13
816	Psychometric properties of a scale to measure investment in the sick role: the Illness Cognitions Scale. Journal of Evaluation in Clinical Practice, 2012, 18, 360-364.	1.8	13
817	Psychomotor depressive symptoms may differentially respond to venlafaxine. International Clinical Psychopharmacology, 2013, 28, 121-126.	1.7	13
818	SLC6A4STin2 VNTR genetic polymorphism is associated with tobacco use disorder, but not with successful smoking cessation or smoking characteristics: a case control study. BMC Genetics, 2014, 15, 78.	2.7	13
819	Association between attributions of responsibility for motor vehicle crashes, depressive symptoms, and return to work.. Rehabilitation Psychology, 2014, 59, 376-385.	1.2	13
820	Association between alcohol consumption and self-reported depression among elderly Australian men. Geriatric Mental Health Care, 2014, 2, 3-8.	0.4	13
821	RF rectifiers for EM power harvesting in a Deep Brain Stimulating device. Australasian Physical and Engineering Sciences in Medicine, 2015, 38, 157-172.	1.4	13
822	Nonsuicidal self-injury in Indian adolescents: Nonexistent or unacknowledged?. International Journal of Social Psychiatry, 2015, 61, 516-517.	3.3	13
823	STin2 VNTR polymorphism is associated with comorbid tobacco use and mood disorders. Journal of Affective Disorders, 2015, 172, 347-354.	4.2	13
824	A novel way to quantify schizophrenia symptoms in clinical trials. European Journal of Clinical Investigation, 2021, 51, e13398.	3.4	13
825	Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression. Drugs and Aging, 2021, 38, 451-467.	2.9	13
826	Diabetes and mood disorders: shared mechanisms and therapeutic opportunities. International Journal of Psychiatry in Clinical Practice, 2022, 26, 183-195.	2.7	13
827	The Specificity of Platelet Glutamate Receptor Supersensitivity in Psychotic Disorders. Life Sciences, 2000, 66, 2427-2432.	4.4	13
828	Selective serotonin reuptake inhibitors in mixed anxiety-depression. International Clinical Psychopharmacology, 2000, 15, S41-S45.	1.7	12

#	ARTICLE	IF	CITATIONS
829	Trichotillomania: response to lithium in a person with comorbid bipolar disorder. <i>Human Psychopharmacology</i> , 2003, 18, 576-577.	1.7	12
830	Recent developments in the treatment of bipolar disorders. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1621-1632.	4.0	12
831	The management of bipolar disorder in primary care: A review of existing and emerging therapies. <i>Psychiatry and Clinical Neurosciences</i> , 2005, 59, 229-239.	2.2	12
832	Seasonal influences on first-episode admission in affective and non-affective psychosis. <i>Acta Neuropsychiatrica</i> , 2006, 18, 154-161.	2.2	12
833	The Bipolar Comprehensive Outcomes Study (BCOS): Baseline findings of an Australian cohort study. <i>Journal of Affective Disorders</i> , 2008, 107, 135-144.	4.2	12
834	Glutamate cysteine ligase (GCL) and self reported depression: An association study from the HUNT. <i>Journal of Affective Disorders</i> , 2011, 131, 207-213.	4.2	12
835	The impact of past direct-personal traumatic events on 12-month outcome in first episode psychotic mania: Trauma and early psychotic mania. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 1017-1024.	2.7	12
836	Trajectory and predictors of quality of life in first episode psychotic mania. <i>Journal of Affective Disorders</i> , 2016, 195, 148-155.	4.2	12
837	Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 1-6.	1.5	12
838	Indices of insulin resistance and glucotoxicity are not associated with bipolar disorder or major depressive disorder, but are differently associated with inflammatory, oxidative and nitrosative biomarkers. <i>Journal of Affective Disorders</i> , 2017, 222, 185-194.	4.2	12
839	Recalibrating the risks and benefits of lithium therapy. <i>British Journal of Psychiatry</i> , 2017, 211, 1-2.	3.5	12
840	Gender-specific risk factors for low bone mineral density in patients taking antipsychotics for psychosis. <i>Human Psychopharmacology</i> , 2018, 33, e2648.	1.7	12
841	Association of depression with mortality in an elderly treated hypertensive population. <i>International Psychogeriatrics</i> , 2019, 31, 371-381.	1.1	12
842	A Neuroethics Framework for the Australian Brain Initiative. <i>Neuron</i> , 2019, 101, 365-369.	8.0	12
843	The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101486.	2.1	12
844	TinyFSCV: FSCV for the Masses. <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2020, 28, 133-142.	5.0	12
845	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. <i>Life Sciences</i> , 2020, 262, 118541.	4.4	12
846	A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder. <i>Journal of Affective Disorders</i> , 2020, 265, 233-238.	4.2	12

#	ARTICLE	IF	CITATIONS
847	Cumulative Cardiovascular Disease Risk and Triglycerides Differentially Relate to Subdomains of Executive Function in Bipolar Disorder; preliminary findings. <i>Journal of Affective Disorders</i> , 2021, 278, 556-562.	4.2	12
848	A Review of the Global Impact of the COVID-19 Pandemic on Public Mental Health, with a Comparison Between the USA, Australia, and Poland with Taiwan and Thailand. <i>Medical Science Monitor</i> , 2021, 27, e932220.	1.1	12
849	The influence of childhood trauma on the treatment outcomes of pharmacological and/or psychological interventions for adolescents and adults with bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 296, 350-362.	4.2	12
850	N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms. <i>Schizophrenia Bulletin</i> , 2022, 48, 1263-1272.	4.5	12
851	SILICA PREGNANULOMA. <i>Archives of Dermatology</i> , 1955, 71, 645.	0.6	11
852	Clozapine Associated Neutropenia and Cytomegalovirus Colitis. <i>Pharmacopsychiatry</i> , 1998, 31, 236-237.	3.4	11
853	The platelet intracellular calcium response to serotonin in subsyndromal depression. <i>International Clinical Psychopharmacology</i> , 1998, 13, 107-110.	1.7	11
854	Pharmacotherapy of mania: A review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 171-193.	2.7	11
855	'Bipolar missed states': the diagnosis and clinical salience of bipolar mixed states. <i>Australian and New Zealand Journal of Psychiatry</i> , 2005, 39, 215-221.	2.7	11
856	When illness does not get better: do we need a palliative psychiatry?. <i>Acta Neuropsychiatrica</i> , 2008, 20, 165-166.	2.2	11
857	Levels of neuregulin 1 and 3 proteins in Brodmann's area 46 from subjects with schizophrenia and bipolar disorder. <i>Neuroscience Letters</i> , 2009, 466, 27-29.	2.1	11
858	Duloxetine 60mg/day for the prevention of depressive recurrences: post hoc analyses from a recurrence prevention study. <i>International Journal of Clinical Practice</i> , 2010, 64, 719-726.	1.7	11
859	The validity and internal structure of the Bipolar Depression Rating Scale: data from a clinical trial of N-acetylcysteine as adjunctive therapy in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2010, 22, 237-242.	2.2	11
860	Do we need to flick the switch? The need for a broader conceptualization of iatrogenic course aggravation in clinical trials of bipolar disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2010, 64, 367-371.	2.2	11
861	Should antipsychotics take pole position in mania treatment?. <i>Lancet, The</i> , 2011, 378, 1279-1281.	12.1	11
862	Prevention of Schizophrenia--Will a Broader Prevention Agenda Support This Aim?. <i>Schizophrenia Bulletin</i> , 2014, 40, 237-239.	4.5	11
863	The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial. <i>Trials</i> , 2014, 15, 425.	1.6	11
864	Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. <i>Psychiatry Research</i> , 2015, 230, 982-983.	3.4	11

#	ARTICLE	IF	CITATIONS
865	Cognitive Dysfunction in Patients With Late-Life Somatic Symptom Disorder: A Comparison According to Disease Severity. <i>Psychosomatics</i> , 2015, 56, 486-494.	2.5	11
866	The prevalence and age of onset of psychiatric disorders in Australian men. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 678-684.	2.7	11
867	The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 165.	1.6	11
868	Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled Trial. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 306-318.	2.2	11
869	A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 262-273.	2.2	11
870	Effects of N-Acetyl Cysteine on Suicidal Ideation in Bipolar Depression. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e665-e665.	2.3	11
871	Microdialysis and microperfusion electrodes in neurologic disease monitoring. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 52.	5.1	11
872	Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 615-627.	4.5	11
873	Attachment insecurity partially mediates the relationship between childhood trauma and depression severity in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 591-603.	4.5	11
874	Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. <i>European Neuropsychopharmacology</i> , 2022, 60, 91-99.	1.6	11
875	Feasibility, Acceptability, and Safety of Faecal Microbiota Transplantation in the Treatment of Major Depressive Disorder: A Pilot Randomized Controlled Trial. <i>Canadian Journal of Psychiatry</i> , 2023, 68, 315-326.	2.2	11
876	Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2024, 58, 70-81.	2.7	11
877	Pharmacotherapy of bipolar disorder: the role of atypical antipsychotics and experimental strategies. <i>Human Psychopharmacology</i> , 2002, 17, 407-412.	1.7	10
878	Combination pharmacotherapy in unipolar depression. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1049-1060.	2.8	10
879	Effects of a walking program in the psychiatric in-patient treatment setting: a cohort study. <i>Health Promotion Journal of Australia</i> , 2007, 18, 39-42.	1.4	10
880	Oxidative biology: new intervention opportunities in psychiatry. <i>Acta Neuropsychiatrica</i> , 2007, 19, 259-260.	2.2	10
881	Modeling gene-environment interaction in longitudinal data: Risk for neuroticism due to interaction between maternal care and the Dopamine 4 Receptor gene (DRD4). <i>Australian Journal of Psychology</i> , 2011, 63, 18-25.	2.8	10
882	Acceptance and commitment therapy for treatment-resistant depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 1198-1199.	2.7	10

#	ARTICLE	IF	CITATIONS
883	Evaluating discussion board engagement in the MoodSwings online self-help program for bipolar disorder: protocol for an observational prospective cohort study. <i>BMC Psychiatry</i> , 2015, 15, 243.	2.6	10
884	A cluster analytic approach to identifying predictors and moderators of psychosocial treatment for bipolar depression: Results from STEP-BD. <i>Journal of Affective Disorders</i> , 2016, 203, 152-157.	4.2	10
885	Progressing MoodSwings. The upgrade and evaluation of MoodSwings 2.0: An online intervention for bipolar disorder. <i>Contemporary Clinical Trials</i> , 2017, 56, 18-24.	1.9	10
886	Getting RID of the blues: Formulating a Risk Index for Depression (RID) using structural equation modeling. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 1121-1133.	2.7	10
887	Personality disorder is an excess risk factor for physical multimorbidity among women with mental state disorders. <i>Psychiatry Research</i> , 2017, 257, 546-549.	3.4	10
888	Personality: Distraction or driver in the diagnosis of depression. <i>Personality and Mental Health</i> , 2018, 12, 126-130.	1.5	10
889	Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol). <i>International Journal of Bipolar Disorders</i> , 2018, 6, 11.	2.2	10
890	Falls and Depression in Men: A Population-Based Study. <i>American Journal of Men's Health</i> , 2018, 12, 14-18.	1.6	10
891	An investigation into closed-loop treatment of neurological disorders based on sensing mitochondrial dysfunction. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2018, 15, 8.	4.7	10
892	Improving functional outcomes in early-stage bipolar disorder: The protocol for the REsearch into COgnitive and behavioural VERsatility trial. <i>Microbial Biotechnology</i> , 2019, 13, 1470-1479.	1.9	10
893	Validity of self-reported cancer: Comparison between self-report versus cancer registry records in the Geelong Osteoporosis Study. <i>Cancer Epidemiology</i> , 2020, 68, 101790.	2.1	10
894	Be You: A national education initiative to support the mental health of Australian children and young people. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 1061-1066.	2.7	10
895	The effect of concomitant benzodiazepine use on neurocognition in stable, long-term patients with bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 1005-1016.	2.7	10
896	Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial. <i>Trials</i> , 2020, 21, 14.	1.6	10
897	Studies on Haloperidol and Adjunctive \pm -Mangostin or Raw <i>Garcinia mangostana</i> Linn Pericarp on Bio-Behavioral Markers in an Immune-Inflammatory Model of Schizophrenia in Male Rats. <i>Frontiers in Psychiatry</i> , 2020, 11, 121.	2.7	10
898	Anticonvulsant use and bone health in a population-based study of men and women: cross-sectional data from the Geelong Osteoporosis Study. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 172.	1.9	10
899	The lipid paradox in neuroprogressive disorders: Causes and consequences. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 35-57.	6.6	10
900	What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines. <i>Journal of Affective Disorders</i> , 2022, 298, 565-576.	4.2	10

#	ARTICLE	IF	CITATIONS
901	Intra-Abdominal Egg-Shell Calcifications Due to Silicosis. <i>Radiology</i> , 1956, 67, 527-530.	8.5	9
902	Impact of Pregnancy on Complications of Insulin-Dependent Diabetes Mellitus. <i>American Journal of Perinatology</i> , 1988, 5, 359-367.	1.5	9
903	Evidence-based psychiatric practice: doctrine or trap?. <i>Journal of Evaluation in Clinical Practice</i> , 1999, 5, 149-152.	1.8	9
904	CNS 14-3-3 ⁺ : Changes with sex but not psychiatric diagnoses or psychotropic drug treatment. <i>Schizophrenia Research</i> , 2007, 93, 51-57.	2.0	9
905	Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial. <i>Acta Neuropsychiatrica</i> , 2009, 21, 239-245.	2.2	9
906	Vitamin D: is it relevant to psychiatry?. <i>Acta Neuropsychiatrica</i> , 2009, 21, 205-206.	2.2	9
907	The pharmacological treatment of bipolar disorder in primary care. <i>Medical Journal of Australia</i> , 2010, 193, S24-30.	1.7	9
908	The Impact of Smoking on Clinical Outcomes After First Episode Psychosis: Longer-Term Outcome Findings From the EPPIC 800 Follow-Up Study. <i>Journal of Dual Diagnosis</i> , 2010, 6, 212-234.	1.1	9
909	Clinical Characteristics and Smoking Cessation. <i>Addictive Disorders and Their Treatment</i> , 2013, 12, 158-165.	0.5	9
910	Diagnosis of myalgic encephalomyelitis: where are we now?. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 221-225.	1.6	9
911	Transcultural adaption and validation of the Spanish version of the Bipolar Depression Rating Scale (BDRS-S). <i>Journal of Affective Disorders</i> , 2015, 172, 110-115.	4.2	9
912	Unified selective sorting approach to analyse multi-electrode extracellular data. <i>Scientific Reports</i> , 2016, 6, 28533.	3.4	9
913	The addition of depression to the Framingham Risk Equation model for predicting coronary heart disease risk in women. <i>Preventive Medicine</i> , 2016, 87, 115-120.	3.5	9
914	Social and academic premorbid adjustment domains predict different functional outcomes among youth with first episode mania. <i>Journal of Affective Disorders</i> , 2017, 219, 133-140.	4.2	9
915	Multiplicity of Multi-Bump Type Nodal Solutions for A Class of Elliptic Problems with Exponential Critical Growth in \mathbb{R}^2 . <i>Proceedings of the Edinburgh Mathematical Society</i> , 2017, 60, 273-297.	0.4	9
916	Predictors for clinical deterioration of mental state in patients assessed by telephone-based mental health triage. <i>International Journal of Mental Health Nursing</i> , 2017, 26, 226-237.	4.0	9
917	Evaluation of Modified Patient Health Questionnaire-9 Teen in South African Adolescents. <i>Indian Journal of Psychological Medicine</i> , 2017, 39, 143-145.	1.5	9
918	The impact of substance use disorders on recovery from bipolar depression: Results from the Systematic Treatment Enhancement Program for Bipolar Disorder psychosocial treatment trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 847-855.	2.7	9

#	ARTICLE	IF	CITATIONS
919	Incidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 142-150.	2.4	9
920	Association of direct and indirect aggression and victimization with self-harm in young adolescents: A person-oriented approach. <i>Development and Psychopathology</i> , 2019, 31, 727-739.	2.7	9
921	Mapping Cancer incidence across Western Victoria: the association with age, accessibility, and socioeconomic status among men and women. <i>BMC Cancer</i> , 2019, 19, 892.	2.6	9
922	N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 555.	1.6	9
923	Clinical and demographic characteristics of people who smoke versus inject crystalline methamphetamine in Australia: Findings from a pharmacotherapy trial. <i>Drug and Alcohol Review</i> , 2021, 40, 1249-1255.	2.3	9
924	Anti-inflammatory treatment of bipolar depression: promise and disappointment. <i>Lancet Psychiatry</i> , the, 2020, 7, 467-468.	7.6	9
925	Systematic review and meta-analysis of the role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders. <i>Journal of Affective Disorders</i> , 2021, 279, 711-721.	4.2	9
926	Assessing the feasibility of an m-Health intervention for changing diet quality and mood in individuals with depression: the My Food & Mood program. <i>International Review of Psychiatry</i> , 2021, 33, 266-279.	2.8	9
927	Variations in seasonal solar insolation are associated with a history of suicide attempts in bipolar I disorder. <i>International Journal of Bipolar Disorders</i> , 2021, 9, 26.	2.2	9
928	Depression, diet and exercise. <i>Medical Journal of Australia</i> , 2012, 1, 21-23.	1.7	9
929	Transitions of women's substance use recovery networks and 12-month sobriety outcomes. <i>Social Networks</i> , 2020, 63, 1-10.	2.2	9
930	The pharmacology of bipolar disorder during pregnancy and breastfeeding. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 221-229.	2.5	9
931	Routine outcome measurement by mental health-care providers. <i>Lancet, The</i> , 2003, 361, 1137-1138.	12.1	8
932	Antidepressants and adolescents: the bipolar confound?. <i>Human Psychopharmacology</i> , 2005, 20, 1-2.	1.7	8
933	Antidepressants and the placebo response. <i>Human Psychopharmacology</i> , 2005, 20, 305-307.	1.7	8
934	Early intervention in bipolar disorders. <i>Acta Neuropsychiatrica</i> , 2007, 19, 68-69.	2.2	8
935	Description and Qualitative Evaluation of Jigsaw, an Integrated Young Persons' Mental Health Program. <i>Australasian Psychiatry</i> , 2009, 17, 480-483.	0.9	8
936	Design and analysis of an antenna for wireless energy harvesting in a head-mountable DBS device. , 2013, 2013, 3078-81.		8

#	ARTICLE	IF	CITATIONS
937	High impact child abuse may predict risk of elevated suicidality during antidepressant initiation. Australian and New Zealand Journal of Psychiatry, 2013, 47, 1191-1195.	2.7	8
938	Construct validity of the Experiences of Therapy Questionnaire (ETQ). BMC Psychiatry, 2014, 14, 369.	2.6	8
939	Extreme attributions predict suicidal ideation and suicide attempts in bipolar disorder: prospective data from STEP-BD. World Psychiatry, 2014, 13, 95-96.	9.6	8
940	Regulators of mitochondrial complex I activity: A review of literature and evaluation in postmortem prefrontal cortex from patients with bipolar disorder. Psychiatry Research, 2016, 236, 148-157.	3.4	8
941	Does irritability determine mood depending on age?. Australian and New Zealand Journal of Psychiatry, 2017, 51, 215-216.	2.7	8
942	Hierarchical estimation of neural activity through explicit identification of temporally synchronous spikes. Neurocomputing, 2017, 249, 299-313.	6.1	8
943	Could Lithium in Drinking Water Reduce the Incidence of Dementia?. JAMA Psychiatry, 2017, 74, 983.	11.3	8
944	Mental health information online: what we have learned from social media metrics in BuzzFeed's Mental Health Week. Trends in Psychiatry and Psychotherapy, 2018, 40, 326-336.	0.9	8
945	Has the sun set for seasonal affective disorder and HPA axis studies? A systematic review and future prospects. Journal of Affective Disorders, 2019, 256, 584-593.	4.2	8
946	Lessons from Iceland: Developing scalable and sustainable community approaches for the prevention of mental disorders in young Australians. Mental Health and Prevention, 2019, 15, 200166.	1.3	8
947	Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2019, 17, 297-307.	2.1	8
948	Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study. CNS Drugs, 2019, 33, 685-694.	6.1	8
949	Efficacy of adjunctive <i>Garcinia mangostana</i> Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial. Revista Brasileira De Psiquiatria, 2019, 41, 245-253.	2.7	8
950	Explanatory style in youth self-harm: an Indian qualitative study to inform intervention design. Evidence-Based Mental Health, 2020, 23, 100-106.	5.4	8
951	Personality disorder increases risk of low quality of life among women with mental state disorders. Comprehensive Psychiatry, 2020, 102, 152193.	3.3	8
952	Responsible innovation in technology for mental health care. Lancet Psychiatry, the, 2020, 7, 728-730.	7.6	8
953	Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain. Journal of Clinical Medicine, 2021, 10, 4095.	2.5	8
954	Association Between Vitamin D Insufficiency and Metabolic Syndrome in Patients With Psychotic Disorders. Psychiatry Investigation, 2018, 15, 396-401.	1.6	8

#	ARTICLE	IF	CITATIONS
955	FMT for psychiatric disorders: Following the brown brick road into the future. <i>Bipolar Disorders</i> , 2021, 23, 651-655.	2.4	8
956	Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder. <i>Frontiers in Pharmacology</i> , 2022, 13, 873271.	3.6	8
957	Investing in Late-Life Brain Capital. <i>Innovation in Aging</i> , 2022, 6, .	0.1	8
958	Effects of Psychotropic Drugs on Ribosomal Genes and Protein Synthesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7180.	4.2	8
959	Childhood trauma and depressive symptoms in bipolar disorder: A network analysis. <i>Acta Psychiatrica Scandinavica</i> , 2023, 147, 286-300.	4.5	8
960	Selective Serotonin Reuptake Inhibitor-Induced Disturbances of Haemostasis. <i>CNS Drugs</i> , 1998, 10, 441-446.	6.1	7
961	The platelet intracellular calcium response to serotonin and thrombin in patients with panic disorder. <i>European Neuropsychopharmacology</i> , 1999, 9, 107-110.	1.6	7
962	Detached from attachment: neurobiology and phenomenology have a human face. <i>Acta Neuropsychiatrica</i> , 2010, 22, 202-206.	2.2	7
963	Dimensions of improvement in a clinical trial of N-acetyl cysteine for bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2011, 23, 87-88.	2.2	7
964	Who's left? Symptoms of schizophrenia that predict clinical trial dropout. <i>Human Psychopharmacology</i> , 2011, 26, 609-613.	1.7	7
965	Is "Depression" the new "Neurosis"? <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 297-298.		7
966	Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity. <i>Redox Report</i> , 2014, 19, 232-241.	4.6	7
967	South African adolescents' beliefs about depression. <i>International Journal of Social Psychiatry</i> , 2016, 62, 198-200.	3.3	7
968	Ketamine and rapidly acting antidepressants: Breaking the speed of sound or light?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1026-1029.	2.7	7
969	ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis. <i>Trials</i> , 2019, 20, 658.	1.6	7
970	Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 14-21.	2.7	7
971	Opportunities in the Australian national education initiative for promoting mental health in schools. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 11-13.	5.5	7
972	Dietary tryptophan and bone health: a cross-sectional, population-based study. <i>Archives of Osteoporosis</i> , 2020, 15, 167.	2.5	7

#	ARTICLE	IF	CITATIONS
973	Transcriptional Effects of Psychoactive Drugs on Genes Involved in Neurogenesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8333.	4.2	7
974	A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol. <i>BMC Psychiatry</i> , 2020, 20, 397.	2.6	7
975	The rebirth of lithium as the archetypal mood stabilizer. <i>Bipolar Disorders</i> , 2021, 23, 211-212.	2.4	7
976	Building brain capital. <i>Neuron</i> , 2021, 109, 1430-1432.	8.0	7
977	Biomarkers for Deep Brain Stimulation in Animal Models of Depression. <i>Neuromodulation</i> , 2022, 25, 161-170.	0.9	7
978	Early intervention comes late. <i>European Neuropsychopharmacology</i> , 2022, 59, 1-3.	1.6	7
979	Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression. <i>Acta Neuropsychiatrica</i> , 2022, 34, 220-227.	2.2	7
980	Brain derived neurotrophic factor in perioperative neurocognitive disorders: Current evidence and future directions. <i>Neurobiology of Learning and Memory</i> , 2022, 193, 107656.	2.0	7
981	The effect of depressive symptoms on disability-free survival in healthy older adults: A prospective cohort study. <i>Acta Psychiatrica Scandinavica</i> , 2023, 147, 92-104.	4.5	7
982	Spectral indices of cardiovascular adaptations to short-term simulated microgravity exposure. <i>Integrative Psychological and Behavioral Science</i> , 1995, 30, 201-214.	0.9	6
983	Serotonergic syndrome after concomitant use of moclobemide and fluoxetine. <i>Human Psychopharmacology</i> , 1996, 11, 146-147.	1.7	6
984	Review: rapid cycling bipolar disorder associated with female gender and bipolar type II subgroup. <i>Evidence-Based Mental Health</i> , 2004, 7, 91-91.	5.4	6
985	An audit of clinical outcomes and client and referrer satisfaction with a Mood and Anxiety Disorders Unit. <i>Journal of Evaluation in Clinical Practice</i> , 2004, 10, 549-552.	1.8	6
986	Mood stabilizers: a labile label. <i>Acta Psychiatrica Scandinavica</i> , 2005, 111, 5-6.	4.5	6
987	Depression and bone mineral density in a community sample of men: Geelong Osteoporosis Study. <i>The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender</i> , 2007, 4, 292-297.	0.3	6
988	Mental health services for young people – the challenge of integrating services. <i>Acta Neuropsychiatrica</i> , 2010, 22, 158-160.	2.2	6
989	Depolarizing Bipolar Disorder: Both the Illness and Our Views. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 909-910.	2.7	6
990	To a broader concept of remission: Rating the health-related quality of life in bipolar disorder. <i>Journal of Affective Disorders</i> , 2013, 150, 673-676.	4.2	6

#	ARTICLE	IF	CITATIONS
991	Treatment of bipolar depression. Medical Journal of Australia, 2013, 199, S32-5.	1.7	6
992	Paraoxonase 1 status and interactions between Q192R functional genotypes by smoking contribute significantly to total plasma radical trapping antioxidant potential. Neuroscience Letters, 2014, 581, 46-51.	2.1	6
993	The impact of insight in a first-episode mania with psychosis population on outcome at 18 months. Journal of Affective Disorders, 2014, 167, 74-79.	4.2	6
994	On the Analysis of Hybrid Designs that Combine Group- and Individual-Level Data. Biometrics, 2015, 71, 227-236.	1.5	6
995	Free-form contour packing based on material grid approximation and lowest-gravity-center methods. Expert Systems With Applications, 2015, 42, 1864-1871.	7.9	6
996	Cognition in psychiatric disorders: from models to management. Lancet Psychiatry, the, 2017, 4, 173-175.	7.6	6
997	Do Sleep Disturbances Predict or Moderate the Response to Psychotherapy in Bipolar Disorder?. Journal of Nervous and Mental Disease, 2017, 205, 196-202.	1.0	6
998	The subjective wellbeing profile of the "preiree"™ demographic: A cross-sectional study. Maturitas, 2018, 110, 111-117.	2.5	6
999	The SMILES trial: an important first step. BMC Medicine, 2018, 16, 237.	5.7	6
1000	Drugs used in the treatment of bipolar disorder and their effects on cholesterol biosynthesis " A possible therapeutic mechanism. World Journal of Biological Psychiatry, 2019, 20, 766-777.	2.7	6
1001	Personality Disorder and Physical Health Comorbidities: A Link With Bone Health?. Frontiers in Psychiatry, 2020, 11, 602342.	2.7	6
1002	Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic. Australian and New Zealand Journal of Psychiatry, 2020, 54, 759-761.	2.7	6
1003	The influence of stage of illness on functional outcomes after psychological treatment in bipolar disorder: A systematic review. Bipolar Disorders, 2020, 22, 666-692.	2.4	6
1004	Hypertensive disorders of pregnancy and risk of asthma in offspring: protocol for a systematic review and meta-analysis. BMJ Open, 2020, 10, e035145.	2.1	6
1005	Design of a brief psychological intervention for youth who self-harm: a formative study in India. Evidence-Based Mental Health, 2021, 24, e2-e2.	5.4	6
1006	Mood Regulatory Actions of Active and Sham Nucleus Accumbens Deep Brain Stimulation in Antidepressant Resistant Rats. Frontiers in Human Neuroscience, 2021, 15, 644921.	2.1	6
1007	Cognitive Profile and Relationship with Quality of Life and Psychosocial Functioning in Mood Disorders. Archives of Clinical Neuropsychology, 2022, 37, 376-389.	0.5	6
1008	The scholarly impact of private sector research: A multivariate analysis. Journal of Informetrics, 2021, 15, 101191.	3.0	6

#	ARTICLE	IF	CITATIONS
1009	Response of obsessive compulsive disorder to carbamazepine in two patients with comorbid epilepsy. <i>Annals of Clinical Psychiatry</i> , 1997, 9, 171-173.	1.5	6
1010	Intertwined associations between oxidative and nitrosative stress and endocannabinoid system pathways: Relevance for neuropsychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110481.	5.0	6
1011	N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 117, 110550.	5.0	6
1012	Scientists Against War: A Plea to World Leaders for Better Governance. <i>Sleep and Vigilance</i> , 2022, 6, 1-6.	0.7	6
1013	Effect of abrupt mitral regurgitation after balloon valvuloplasty on myocardial load and performance. <i>Journal of the American College of Cardiology</i> , 1991, 17, 872-878.	5.5	5
1014	Mitochondrial Dysfunction and Oxidative Stress. , 2010, , 244-254.		5
1015	Termination of therapy: what can clinicians do to maximise gains?. <i>Acta Neuropsychiatrica</i> , 2010, 22, 43-45.	2.2	5
1016	Commentary on "Palliative models of care for later stages of mental disorder: Maximising recovery, maintaining hope and building morale". <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 276-278.	2.7	5
1017	Strengthening the role of convergence science in medicine. <i>Convergent Science Physical Oncology</i> , 2015, 1, 026001.	2.6	5
1018	Effects of Persisting Emotional Impact from Child Abuse and Norepinephrine Transporter Genetic Variation on Antidepressant Efficacy in Major Depression: A Pilot Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 53-61.	2.1	5
1019	The Use of Mixed Methods in Drug Discovery. , 2015, , 59-74.		5
1020	Chronic fatigue syndrome: what is it and how to treat?. <i>Lancet Psychiatry</i> , the, 2015, 2, 1044-1045.	7.6	5
1021	The Classification of Biomarkers. <i>JAMA Psychiatry</i> , 2015, 72, 1056.	11.3	5
1022	Bipolar disorder: defining symptoms and comorbidities " Authors' reply. <i>Lancet, The</i> , 2016, 388, 869-870.	12.1	5
1023	Electrical resistance increases at the tissue-electrode interface as an early response to nucleus accumbens deep brain stimulation. , 2016, 2016, 1814-1817.		5
1024	Pattern of psychotropic medication use over two decades in Australian women. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 1212-1219.	2.7	5
1025	International multi-site survey on the use of online support groups in bipolar disorder. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 473-476.	1.5	5
1026	The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis " CORRIGENDUM. <i>Psychological Medicine</i> , 2018, 48, 528-528.	5.2	5

#	ARTICLE	IF	CITATIONS
1027	Resting regional brain metabolism in social anxiety disorder and the effect of moclobemide therapy. <i>Metabolic Brain Disease</i> , 2018, 33, 569-581.	2.9	5
1028	Pre-onset risk characteristics for mania among young people at clinical high risk for psychosis. <i>Schizophrenia Research</i> , 2018, 192, 345-350.	2.0	5
1029	Psychopathological Features of Bipolar Depression: Italian Validation of the Bipolar Depression Rating Scale (I-BDRS). <i>Frontiers in Psychology</i> , 2018, 9, 1047.	2.2	5
1030	Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. <i>Focus (American Journal of Psychiatry)</i> , 2019, 117, 1000-1009.	0.9	5
1031	The open access mandate: Be careful what you wish for. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 1044-1046.	2.7	5
1032	Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: protocol for a systematic review. <i>BMJ Open</i> , 2019, 9, e025640.	2.1	5
1033	Role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders: a protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e025145.	2.1	5
1034	Treatment-resistant and Multi-therapy resistant criteria for bipolar depression: A consensus definition â€“ CORRIGENDUM. <i>British Journal of Psychiatry</i> , 2019, 214, 309-309.	3.5	5
1035	The Associations between Dairy Product Consumption and Biomarkers of Inflammation, Adipocytokines, and Oxidative Stress in Children: A Cross-Sectional Study. <i>Nutrients</i> , 2020, 12, 3055.	4.2	5
1036	Lithium should be borne in mind: Five key reasons. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 659-663.	2.7	5
1037	Effects of psychoactive drugs on cellular bioenergetic pathways. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 79-93.	2.7	5
1038	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. <i>CNS Spectrums</i> , 2021, 26, 290-298.	1.3	5
1039	Associations between dairy consumption and constipation in adults: A cross-sectional study. <i>Nutrition and Health</i> , 2022, 28, 31-39.	1.7	5
1040	Cognitive ability and metabolic physical health in first-episode psychosis. <i>Schizophrenia Research: Cognition</i> , 2021, 24, 100194.	1.3	5
1041	An Investigation Into Miniaturised Closed-Loop DBS Devices. <i>IEEE Transactions on Medical Robotics and Bionics</i> , 2021, 3, 671-680.	3.3	5
1042	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. <i>CNS Spectrums</i> , 2022, 27, 716-723.	1.3	5
1043	Pharmacological treatment in the early phase of bipolar disorders: what stage are we at?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 199-207.	2.7	5
1044	A clinical monitoring system for clozapine. <i>Australasian Psychiatry</i> , 2006, 14, 156-168.	0.9	5

#	ARTICLE	IF	CITATIONS
1045	Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: PÃ©ricarpe dÃ©™appoint <i>Garcinia mangostana</i> Linn (mangoustan) pour la schizophrÃ©nie : un essai dÃ©™efficacitÃ© de 24 semaines, Ã© double insu, randomisÃ© et contrÃ© par placebo. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 354-366.	2.2	5
1046	Mindfulness-based online intervention to improve quality of life in late-stage bipolar disorder: A randomized clinical trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2021, 89, 830-844.	2.0	5
1047	Dietary quality and nutrient intake in adults with obsessive-compulsive disorder. <i>BJPsych Open</i> , 2021, 7, .	0.7	5
1048	Attentional engagement and inhibitory control according to positive and negative symptoms in schizophrenia: An emotional antisaccade task. <i>Schizophrenia Research</i> , 2022, 239, 142-150.	2.0	5
1049	Effect of Glucocorticoid and 11Î²-Hydroxysteroid-Dehydrogenase Type 1 (11Î²-HSD1) in Neurological and Psychiatric Disorders. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 387-398.	2.1	5
1050	Evaluating telehealth lifestyle therapy versus telehealth psychotherapy for reducing depression in adults with COVID-19 related distress: the curbing anxiety and depression using lifestyle medicine (CALM) randomised non-inferiority trial protocol. <i>BMC Psychiatry</i> , 2022, 22, 219.	2.6	5
1051	Associations of Cardiovascular Agents and Metformin with Depression Symptoms: A Cross-Sectional Analysis from the HUNT Study, Norway. <i>Drugs - Real World Outcomes</i> , 2022, 9, 503-516.	1.7	5
1052	Severe psychiatric disorders and general medical comorbidities: inflammation-related mechanisms and therapeutic opportunities. <i>Clinical Science</i> , 2022, 136, 1257-1280.	4.3	5
1053	The Impact of Posttraumatic Stress Disorder on Pharmacologic Intervention Outcomes for Adults With Bipolar Disorder: A Systematic Review. <i>International Journal of Neuropsychopharmacology</i> , 2023, 26, 61-69.	2.1	5
1054	Psychological distress in siblings of people with mental illness: A systematic review and meta-analysis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2023, 57, 642-660.	2.7	5
1055	CARCINOMATOUS INVOLVEMENT OF THE PERICARDIUM PRODUCING THE SYNDROME OF CONSTRICTIVE PERICARDITIS: REPORT OF A CASE. <i>Annals of Internal Medicine</i> , 1956, 45, 298.	10.0	4
1056	The utility of the Clinical Global Impression Scale in the clinical setting. <i>Acta Neuropsychiatrica</i> , 2006, 18, 301-301.	2.2	4
1057	The place of placebo? The ethics of placebo-controlled trials in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2007, 19, 74-75.	2.2	4
1058	To E or not to E? The case for electronic health records. <i>Acta Neuropsychiatrica</i> , 2008, 20, 104-106.	2.2	4
1059	Duration of untreated psychosis: What are we talking about?. <i>Acta Neuropsychiatrica</i> , 2009, 21, 106-108.	2.2	4
1060	Bipolar disorder: new understandings, emerging treatments. <i>Medical Journal of Australia</i> , 2010, 193, S3-4.	1.7	4
1061	The utility of the Mood Disorders Questionnaire as a screening tool in a methadone maintenance treatment program. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010, 14, 150-153.	2.7	4
1062	The need for specialist services for serious and recurrent mood disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 815-818.	2.7	4

#	ARTICLE	IF	CITATIONS
1063	Investigating the predictive validity of an emergency department mental health triage tool. Australian Journal of Cancer Nursing, 2014, 16, 11-18.	1.6	4
1064	Depolarising bipolarity: Clinical considerations. Australian and New Zealand Journal of Psychiatry, 2015, 49, 767-769.	2.7	4
1065	Wireless Optogenetics: An Exploration of Portable Microdevices for Small Animal Photostimulation. Procedia Technology, 2015, 20, 225-230.	1.1	4
1066	Human l-DOPA decarboxylase mRNA is a target of miR-145: A prediction to validation workflow. Gene, 2015, 554, 174-180.	2.3	4
1067	Conceptual analysis of diabetic retinopathy in Ayurveda. Journal of Ayurveda and Integrative Medicine, 2017, 8, 122-131.	1.8	4
1068	Cognitive functioning following stabilisation from first episode mania. International Journal of Bipolar Disorders, 2017, 5, 39.	2.2	4
1069	The effect of combined treatment with SSRIs and renin-angiotensin system (RAS) drugs: A propensity score matched cohort study. European Neuropsychopharmacology, 2020, 32, 120-130.	1.6	4
1070	Study protocol for the systematic review and meta-analyses of the association between schizophrenia and bone fragility. BMJ Open, 2020, 10, e041859.	2.1	4
1071	A Randomized Controlled Trial of Transcultural Validation of Group-Based Psychosocial Intervention for Patients with Bipolar Disorder. Psychiatry Research, 2020, 290, 113139.	3.4	4
1072	Interleukin-6 and total antioxidant capacity levels following N-acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorder. Acta Neuropsychiatrica, 2020, 32, 313-320.	2.2	4
1073	The evolution of clinical trials in response to COVID-19. Medical Journal of Australia, 2021, 214, 332.	1.7	4
1074	Treatment of Refractory Obsessive-Compulsive Disorder with Nutraceuticals (TRON): A 20-week, open label pilot study. CNS Spectrums, 2021, , 1-35.	1.3	4
1075	Brain Health Living Labs. American Journal of Geriatric Psychiatry, 2021, 29, 698-703.	1.1	4
1076	Finding reviewers: A crisis for journals and their authors. Australian and New Zealand Journal of Psychiatry, 2020, 54, 957-959.	2.7	4
1077	Psychosis continuum and neurocognition in bipolar disorder. Revista Brasileira De Psiquiatria, 2011, 33, 319-320.	2.7	4
1078	Reviving academic psychiatry in Australia and New Zealand. Australian and New Zealand Journal of Psychiatry, 2022, 56, 425-427.	2.7	4
1079	Hypoxia-Reoxygenation Couples 3Î²HSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer. Cancer Research, 2022, 82, 2417-2430.	0.9	4
1080	Predictors of suicidal ideation severity among treatment-seeking young people with major depressive disorder: The role of state and trait anxiety. Australian and New Zealand Journal of Psychiatry, 2023, 57, 1150-1162.	2.7	4

#	ARTICLE	IF	CITATIONS
1081	Can we overcome the heterogeneity of mood disorders in clinical trials?. Australian and New Zealand Journal of Psychiatry, 2023, 57, 309-311.	2.7	4
1082	Health-related quality of life and functioning in bipolar disorder: the impact of pharmacotherapy. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 509-523.	1.4	3
1083	â€œMind and Bodyâ€™: a lifestyle programme for people on antipsychotic medication. Journal of Evaluation in Clinical Practice, 2009, 15, 276-280.	1.8	3
1084	Trauma and psychosis: some aspects of a complex relationship. Acta Neuropsychiatrica, 2009, 21, 148-150.	2.2	3
1085	Writing letters to patients. Acta Neuropsychiatrica, 2009, 21, 314-316.	2.2	3
1086	Pharmacotherapy for co-occurring alcohol and drug disorders in schizophrenia and bipolar disorder: where is the evidence?. Acta Neuropsychiatrica, 2010, 22, 95-97.	2.2	3
1087	Bipolar disorder and adiposity: a study using whole body dual energy X-ray absorptiometry scans. Acta Neuropsychiatrica, 2011, 23, 219-223.	2.2	3
1088	Adaptive Competence-Based System in an E-learning Platform: Adapting Support Tasks to Students. , 2012, , .		3
1089	Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants. Current Medical Research and Opinion, 2013, 29, 827-833.	1.9	3
1090	Neuropsychiatric presentation of Lyme disease in Australia. Australian and New Zealand Journal of Psychiatry, 2013, 47, 397-398.	2.7	3
1091	Clustering of cardiac risk factors associated with the metabolic syndrome and associations with psychosocial distress in a young Asian Indian population. Journal of Behavioral Medicine, 2014, 37, 725-735.	2.2	3
1092	Radio frequency energy harvesting from a feeding source in a passive deep brain stimulation device for murine preclinical research. Medical Engineering and Physics, 2015, 37, 1020-1026.	1.8	3
1093	Mental health system development in Asia: Does Australia have a role?. Australian and New Zealand Journal of Psychiatry, 2016, 50, 834-841.	2.7	3
1094	338. Enabling Precision Psychiatry through â€œomicsâ€™: From Biomarkers to Biological Pathways. Biological Psychiatry, 2017, 81, S138-S139.	1.3	3
1095	Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study. Advances in Integrative Medicine, 2017, 4, 109-114.	1.0	3
1096	Medications With Depression as an Adverse Effect. JAMA - Journal of the American Medical Association, 2018, 320, 1815.	7.0	3
1097	â€œIs â€œearly interventionâ€œ in bipolar disorder what it claims to be?â€™ Malhi etÂˆal. Bipolar Disorders, 2018, 20, 181-183.	2.4	3
1098	Does <i>N</i>-acetylcysteine improve behaviour in children with autism?: A mixed-methods analysis of the effects of <i>N</i>-acetylcysteine. Journal of Intellectual and Developmental Disability, 2019, 44, 474-480.	1.8	3

#	ARTICLE	IF	CITATIONS
1099	Sample selection and reasons for non-participation in the PRedictors and Outcomes of incident FRACtures (PROFRAC) study. <i>Journal of Public Health Research</i> , 2019, 8, 1475.	1.3	3
1100	A Neuroethics Framework for the Australian Brain Initiative. <i>Neuron</i> , 2020, 105, 201.	8.0	3
1101	Clozapine and the Course of Bipolar Disorder in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD): La clozapine et l'évolution du trouble bipolaire dans le Programme d'amélioration systématique du traitement du trouble bipolaire (STEP-BD). <i>Canadian Journal of Psychiatry</i> , 2020, 65, 245-252.	2.2	3
1102	Does guideline-concordant care predict naturalistic outcomes in youth with early stage bipolar I disorder?. <i>Journal of Affective Disorders</i> , 2021, 278, 23-32.	4.2	3
1103	Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 506-516.	2.7	3
1104	The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2021, 12, 626486.	2.7	3
1105	A protocol for the first episode psychosis outcome study (<scp>FEPOS</scp>): a 15-year follow-up after treatment at the <scp>Early Psychosis Prevention and Intervention Centre, Melbourne, Australia</scp>. <i>Microbial Biotechnology</i> , 2022, 16, 715-723.	1.9	3
1106	Increased maternal mental health burden in a representative longitudinal community cohort coinciding with COVID-19 lockdown. <i>Australian Journal of Psychology</i> , 2021, 73, 578-585.	2.8	3
1107	What Injured Workers With Complex Claims Look For in Online Communities: Netnographic Analysis. <i>Journal of Medical Internet Research</i> , 2022, 24, e17180.	4.4	3
1108	A pragmatic preference trial of therapeutic yoga as an adjunct to group cognitive behaviour therapy versus group CBT alone for depression and anxiety. <i>Journal of Affective Disorders</i> , 2022, 307, 1-10.	4.2	3
1109	Depression, anxiety and worry in young Pacific adults in New Zealand during the COVID-19 pandemic. <i>Australian and New Zealand Journal of Psychiatry</i> , 2023, 57, 698-709.	2.7	3
1110	Renewal of academic psychiatry without addressing gender equity will render it Jurassic rather than endangered. <i>Australian and New Zealand Journal of Psychiatry</i> , 2023, 57, 315-321.	2.7	3
1111	The Australian Early Psychosis Collaborative Consortium (AEPC): Improving Clinical Care in Early Psychosis. <i>Australasian Psychiatry</i> , 2023, 31, 306-308.	0.9	3
1112	Behavioural changes in dogs with acral lick dermatitis during a 2 month extension phase of fluoxetine treatment. <i>Human Psychopharmacology</i> , 1998, 13, 435-437.	1.7	2
1113	Platelet Glutamate Receptors as a Window into Psychiatric Disorders. , 2005, , 233-241.		2
1114	Australasian commentary on CANMAT guidelines for treatment of bipolar disorder. <i>Bipolar Disorders</i> , 2005, 7, 83-86.	2.4	2
1115	The impact of age at onset of bipolar 1 disorder on functioning and clinical presentation. <i>Acta Neuropsychiatrica</i> , 2006, 18, 242-243.	2.2	2
1116	Higher dose venlafaxine may improve response compared with standard doses in people with major depressive disorder and intolerance or non-responsiveness to SSRIs. <i>Evidence-Based Mental Health</i> , 2007, 10, 17-17.	5.4	2

#	ARTICLE	IF	CITATIONS
1117	Genetically guided prescribing: Hope or hype?. <i>Acta Neuropsychiatrica</i> , 2008, 20, 50-51.	2.2	2
1118	Validity of the Portuguese version of the Bipolar Depression Rating Scale. <i>Acta Neuropsychiatrica</i> , 2010, 22, 100-101.	2.2	2
1119	Difficult to treat depression. <i>Medical Journal of Australia</i> , 2013, 199, S4-5.	1.7	2
1120	Atypical antipsychotic agents; Peas in a pod or chalk and cheese?. <i>BMC Medicine</i> , 2014, 12, .	5.7	2
1121	N-Acetylcysteine for Huntington's?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 1071-1072.	2.7	2
1122	Vertical stratification and effect of petiole and dry leaf size on arthropod feeding guilds in <i>Cecropia pachystachya</i> (Urticaceae). <i>Brazilian Journal of Biology</i> , 2015, 75, 517-523.	0.9	2
1123	An ISBD perspective on the sociocultural challenges of managing bipolar disorder: A content analysis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 1096-1103.	2.7	2
1124	Protocol update and statistical analysis plan for CADENCE-BZ: a randomized clinical trial to assess the efficacy of sodium benzoate as an adjunctive treatment in early psychosis. <i>Trials</i> , 2019, 20, 203.	1.6	2
1125	Role of the T-Cell Network in Psychiatric Disorders. , 2021, , 109-132.		2
1126	Psychometric Properties of the Chinese Version of the Bipolar Depression Rating Scale for Bipolar Disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 787-795.	2.1	2
1127	Personality disorder among youth with first episode psychotic mania: An important target for specific treatment?. <i>Microbial Biotechnology</i> , 2022, 16, 256-263.	1.9	2
1128	Miniature FSCV Devices: A Review. <i>IEEE Sensors Journal</i> , 2021, 21, 13006-13018.	4.8	2
1129	Why do medications with little or no efficacy continue to be prescribed in the management of patients with bipolar disorder?. <i>Bipolar Disorders</i> , 2021, 23, 541-543.	2.4	2
1130	Mood disorder and cancer onset: evidence from a population-based sample of Australian women. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 355-361.	2.7	2
1131	Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial. <i>Journal of Psychiatric Research</i> , 2021, 142, 376-383.	3.2	2
1132	Recent developments in the treatment of bipolar disorders. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1621-1632.	4.0	2
1133	Acute management of bipolar disorders. <i>Australian Prescriber</i> , 2008, 31, 73-76.	1.0	2
1134	Treatment of bipolar depression. <i>Medical Journal of Australia</i> , 2012, 1, 32-35.	1.7	2

#	ARTICLE	IF	CITATIONS
1135	A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking. <i>European Neuropsychopharmacology</i> , 2021, 53, 120-126.	1.6	2
1136	Bipolar disorder and bone health: A case-control study. <i>Journal of Affective Disorders</i> , 2022, 308, 39-43.	4.2	2
1137	Common effects of bipolar disorder medications on expression quantitative trait loci genes. <i>Journal of Psychiatric Research</i> , 2022, 150, 105-112.	3.2	2
1138	Psychographic Segmentation: Another Lever for Precision Population Brain Health. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 783297.	3.5	2
1139	Mixed Methods Thematic Analysis of a Randomised Controlled Trial of Adjunctive Mitochondrial Agents for Bipolar Depression. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022, 20, 300-310.	2.1	2
1140	Integrative Analyses of Transcriptomes to Explore Common Molecular Effects of Antipsychotic Drugs. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7508.	4.2	2
1141	Personality traits as mediators of the relationship between childhood trauma and depression severity in bipolar disorder: A structural equation model. <i>Australian and New Zealand Journal of Psychiatry</i> , 2023, 57, 1031-1042.	2.7	2
1142	Isolating the impact of antipsychotic medication on metabolic health: Secondary analysis of a randomized controlled trial of antipsychotic medication versus placebo in antipsychotic medication naïve first-episode psychosis (the STAGES study). <i>Microbial Biotechnology</i> , 2023, 17, 597-607.	1.9	2
1143	Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline Treatment. <i>Clinical Psychopharmacology and Neuroscience</i> , 2024, 22, 33-44.	2.1	2
1144	Fiber intake and fiber intervention in depression and anxiety: a systematic review and meta-analysis of observational studies and randomized controlled trials. <i>Nutrition Reviews</i> , 0, , .	5.9	2
1145	SmartFSCV: An Artificial Intelligence Enabled Miniaturised FSCV Device Targeting Serotonin. <i>IEEE Open Journal of Engineering in Medicine and Biology</i> , 2024, 5, 75-85.	2.5	2
1146	Enhanced blockade of $^{45}\text{Ca}^{2+}$ uptake into platelets in manic patients with bipolar affective disorder with flunarazine and verapamil. <i>Human Psychopharmacology</i> , 1995, 10, 299-303.	1.7	1
1147	P.2.009 A prospective randomised double blind controlled study of the efficacy of Lorazepam versus clothiapine in the control of acutely behaviorally disturbed patients. <i>European Neuropsychopharmacology</i> , 1997, 7, S197.	1.6	1
1148	Mood disorders: mechanisms and pathophysiology. <i>Acta Neuropsychiatrica</i> , 2003, 15, 307-308.	2.2	1
1149	The platelet window: examining receptor regulated second messenger processes in psychosis and depression. <i>Acta Neuropsychiatrica</i> , 2003, 15, 309-315.	2.2	1
1150	Clinical Characteristics and Management of Bipolar Disorder in Women across the Life Span. <i>Women's Health</i> , 2005, 1, 421-428.	1.5	1
1151	SSRI use and bone mineral density in women with a history of depression: Geelong Osteoporosis Study. <i>Acta Neuropsychiatrica</i> , 2006, 18, 311-312.	2.2	1
1152	Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression. <i>Evidence-Based Mental Health</i> , 2006, 9, 42-42.	5.4	1

#	ARTICLE	IF	CITATIONS
1153	Brain-derived neurotrophic factor: a modifiable common mediator in both the pathophysiology of psychiatric illness and in successful pharmacological treatments. <i>Acta Neuropsychiatrica</i> , 2008, 20, 223-225.	2.2	1
1154	Rhythm and blues. <i>Acta Neuropsychiatrica</i> , 2008, 20, 319-320.	2.2	1
1155	PHP24 USE OF THE AMCP FORMAT IN THE U.S.:A NATIONAL SURVEY OF HEALTH PLANS. <i>Value in Health</i> , 2008, 11, A369.	0.3	1
1156	Preventive strategies in bipolar disorders: identifying targets for early intervention. , 0, , 223-240.		1
1157	Suicidality â€œ the challenge for public mental health services. <i>Acta Neuropsychiatrica</i> , 2009, 21, 41-43.	2.2	1
1158	Rapid Cycling Bipolar Disorder: Phenomenology and Treatment. , 2010, , 333-341.		1
1159	Deserves a hearing? A case report of remitting tinnitus with N-acetyl cysteine. <i>African Journal of Psychiatry</i> , 2013, 16, 238, 240.	0.1	1
1160	Treatment of bipolar depression. <i>Medical Journal of Australia</i> , 2013, 198, 139-139.	1.7	1
1161	Bipolar disorder. , 2014, , 153-165.		1
1162	Structure/Agency and the Anthropology of the Middle East. , 2015, , 40-71.		1
1163	Biological models of mental illness: implications for therapy development. <i>Medical Journal of Australia</i> , 2016, 204, 339-340.	1.7	1
1164	First-Episode Schizophrenia and Diabetes Risk. <i>JAMA Psychiatry</i> , 2017, 74, 761.	11.3	1
1165	Clinical research and the medical research future fund. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 863-865.	2.7	1
1166	S204. NUTRITIONAL DEFICIENCIES AND CLINICAL CORRELATES IN FIRST-EPISODE PSYCHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S405-S405.	4.5	1
1167	The Future of Psychiatry Commission. <i>Lancet Psychiatry</i> ,the, 2018, 5, 13.	7.6	1
1168	A case of antibioticâ€œassociated mania in a 67â€œyearâ€œold woman. <i>Bipolar Disorders</i> , 2019, 21, 670-672.	2.4	1
1169	Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e035080.	2.1	1
1170	The Added Burden of Personality Disorder on Subsidized Australian Health Service Utilization Among Women With Mental State Disorder. <i>Frontiers in Global Women S Health</i> , 2021, 2, 615057.	2.4	1

#	ARTICLE	IF	CITATIONS
1171	Not in education, employment and training status in the early stages of bipolar I disorder with psychotic features. <i>Microbial Biotechnology</i> , 2022, 16, 609-617.	1.9	1
1172	Leveraging Convergence Science to Address Global Mental Health Challenges. , 2021, , 7-28.		1
1173	Analyzing leukocyte telomere length in bipolar disorder: Authors'™ reply. <i>Revista Brasileira De Psiquiatria</i> , 2017, 39, 275-276.	2.7	1
1174	Silencing of Stearoyl-CoA Desaturase Inhibits Proliferation and Induces Apoptosis in Human Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2008, 103, S146.	0.4	1
1175	The specific phenotype of depression in recent onset schizophrenia spectrum disorders: A symptom profile and network comparison to recent onset major depressive disorder without psychotic features. <i>Schizophrenia Research</i> , 2022, 240, 52-60.	2.0	1
1176	The Moo'™D Study: protocol for a randomised controlled trial of A2 beta-casein only versus conventional dairy products in women with low mood. <i>Trials</i> , 2021, 22, 899.	1.6	1
1177	Fluoxetine treatment of acral lick dermatitis in dogs: A placebo'€controlled randomized double blind trial. <i>Depression and Anxiety</i> , 1998, 8, 21-23.	4.1	1
1178	Cost-Utility and Cost-effectiveness of MoodSwings 2.0, an Internet-Based Self-management Program for Bipolar Disorder: Economic Evaluation Alongside a Randomized Controlled Trial. <i>JMIR Mental Health</i> , 2022, 9, e36496.	3.4	1
1179	Anxiety and depression symptoms, albuminuria and risk of acute myocardial infarction in the Norwegian HUNT cohort study. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	1.7	1
1180	Anxiety disorders are associated with reduced bone mineral density in men: Findings from the Geelong Osteoporosis Study. <i>Acta Psychiatrica Scandinavica</i> , 2023, 148, 47-59.	4.5	1
1181	Fair funding for mental health research. <i>Australian and New Zealand Journal of Psychiatry</i> , 0, , 000486742311772.	2.7	1
1182	The Impact of N-acetylcysteine on Major Depression: Qualitative Observation and Mixed Methods Analysis of Participant Change during a 12-week Randomised Controlled Trial. <i>Clinical Psychopharmacology and Neuroscience</i> , 2023, 21, 320-331.	2.1	1
1183	Does Post-traumatic Stress Disorder Impact Treatment Outcomes within a Randomised Controlled Trial of Mitochondrial Agents for Bipolar Depression?. <i>Clinical Psychopharmacology and Neuroscience</i> , 2023, 21, 457-465.	2.1	1
1184	Person-centred growth-oriented language and care: Fundamental to successful mental health reform. <i>Australasian Psychiatry</i> , 2023, 31, 598-600.	0.9	1
1185	Distress, burden, and wellbeing in siblings of people with mental illness: a mixed studies systematic review and meta-analysis. <i>Psychological Medicine</i> , 2023, 53, 6945-6964.	5.2	1
1186	The Influence of Personality Disorder Symptoms on Treatment Outcomes in Bipolar Disorder: A Secondary Analysis of a Randomised Controlled Trial: L'™influence des sympt'™mes du trouble de la personnalit'™ sur les r'sultats du traitement dans le trouble bipolaire : Une analyse secondaire d'un essai randomis'™ contr'™l'™. <i>Canadian Journal of Psychiatry</i> , 2024, 69, 275-287.	2.2	1
1187	Israel'™Palestine Conflict: Risk of Sleep Disorders and Post-Traumatic Stress Disorders. <i>Sleep and Vigilance</i> , 0, , .	0.7	1
1188	Effects of antipsychotic drugs on energy metabolism. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2024, 274, 1125-1135.	3.4	1

#	ARTICLE	IF	CITATIONS
1189	Reduced mitochondrial respiratory capacity in patients with acute episodes of bipolar disorder: Could bipolar disorder be a state-dependent mitochondrial disease?. <i>Acta Psychiatrica Scandinavica</i> , 2024, 149, 52-64.	4.5	1
1190	Harbingers of hope: Scientists and the pursuit of world peace. <i>Clinical Psychology in Europe</i> , 2023, 5, .	1.2	1
1191	Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 0, , .	4.5	1
1192	Ondansetron inhibits seizure activity with electroconvulsive therapy: a case report. <i>Human Psychopharmacology</i> , 1999, 14, 213-213.	1.7	0
1193	Depression therapy: Future prospects. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 281-286.	2.7	0
1194	The role of genetics in suicide and the link with major depression and alcoholism. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 275-280.	2.7	0
1195	Predictive Testing for Huntington's Disease: How Does it Impact on Cognitive Performance?. <i>South African Journal of Psychology</i> , 2002, 32, 39-47.	2.2	0
1196	American Psychiatric Association practice guidelines for the treatment of psychiatric disorders: Compendium 2002. <i>Australian and New Zealand Journal of Psychiatry</i> , 2003, 37, 499-499.	2.7	0
1197	Time course of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. <i>Acta Neuropsychiatrica</i> , 2006, 18, 248-248.	2.2	0
1198	05-03 Disease burden of bipolar and schizoaffective disorder in an Australian cohort. <i>Acta Neuropsychiatrica</i> , 2006, 18, 325-325.	2.2	0
1199	Pilot study of physical activity in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2006, 18, 300-301.	2.2	0
1200	Self-reported depression and reduced bone mineral density in a community sample of men: Geelong Osteoporosis Study. <i>Acta Neuropsychiatrica</i> , 2006, 18, 293-294.	2.2	0
1201	Clozapine and cardiotoxicity: echocardiography findings from Barwon Health. <i>Acta Neuropsychiatrica</i> , 2006, 18, 249-250.	2.2	0
1202	A descriptive interview with 64 patients discharged from an acute psychiatric inpatient service. <i>Journal of Evaluation in Clinical Practice</i> , 2008, 14, 990-995.	1.8	0
1203	A Pilot Study of at-risk Criteria for Bipolar Disorders in Help Seeking Adolescents and Young Adults. <i>European Psychiatry</i> , 2009, 24, .	0.2	0
1204	Response to: Retinol-binding Protein 4 Concentrations in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 232.	2.3	0
1205	Bipolar disorder supplement needed broader perspective. <i>Medical Journal of Australia</i> , 2011, 194, 326-326.	1.7	0
1206	ANZJP this Month. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 907-908.	2.7	0

#	ARTICLE	IF	CITATIONS
1207	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of Clinical Practice. Clinical Practice (London, England), 2017, 18, 1-3.	0.784314	0
1208	Adjunctive antioxidants for bipolar disorder. The Cochrane Library, 2017, 1, 1-3.	2.8	0
1209	Temporal Order Assessment in Patients with Bipolar Disorder. Procedia, Social and Behavioral Sciences, 2014, 126, 216.	0.5	0
1210	Editorial (Thematic Issue: Mitochondrial Dysfunction and Its Relation to Translocator Protein, Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 353-354.	2.6	0
1211	Prescription Drug Use. , 0, , 1-3.		0
1212	A Cost-effectiveness model to Guide Health policy in Bipolar Disorder Treatment. Value in Health, 2015, 18, A122.	0.3	0
1213	Editorial (Thematic Issue : Gut Permeability and the Microbiome: Emerging Roles in CNS Function in) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 627 1.8	1.8	0
1214	PM485. Association between erythrocyte membrane fatty acids and psychopathology in individuals at ultra-high risk for psychosis. International Journal of Neuropsychopharmacology, 2016, 19, 76-77.	2.1	0
1215	PM486. Disrupting GluR2-GAPDH Interaction Affects Axon and Dendrite Development. International Journal of Neuropsychopharmacology, 2016, 19, 76-77.	2.1	0
1216	PS229. The use of statins for the treatment of depression in patients with acute coronary syndrome. International Journal of Neuropsychopharmacology, 2016, 19, 83-84.	2.1	0
1217	Hyperthermia for Major Depressive Disorder?. JAMA Psychiatry, 2016, 73, 1095.	11.3	0
1218	Gut dysbiosis in mania: A viable therapeutic target?. Australian and New Zealand Journal of Psychiatry, 2016, 50, 185-185.	2.7	0
1219	508. Perturbations in the Apoptotic Pathway and Mitochondrial Network Dynamics in Peripheral Blood Mononuclear Cells from Bipolar Disorder Patients. Biological Psychiatry, 2017, 81, S206-S207.	1.3	0
1220	980. Insulin is a State Biomarker in Major Depressive Disorder: A Systematic Review and Meta-Analysis. Biological Psychiatry, 2017, 81, S396-S397.	1.3	0
1221	Response to "Pitfalls of big data". Australian and New Zealand Journal of Psychiatry, 2018, 52, 604-605.	2.7	0
1222	S219. RISK FACTORS FOR LOW BONE MINERAL DENSITY IN PATIENTS TAKING ANTIPSYCHOTICS. Schizophrenia Bulletin, 2018, 44, S411-S411.	4.5	0
1223	T159. ASSOCIATION BETWEEN VITAMIN D INSUFFICIENCY AND METABOLIC SYNDROME IN PATIENTS WITH PSYCHOTIC DISORDERS. Schizophrenia Bulletin, 2018, 44, S177-S178.	4.5	0
1224	ANZJP this month September 2019: Acculturating the brain?. Australian and New Zealand Journal of Psychiatry, 2019, 53, 833-834.	2.7	0

#	ARTICLE	IF	CITATIONS
1225	First episode mania: we should have intervened earlier. <i>Lancet Psychiatry</i> , 2019, 6, 807-808.	7.6	0
1226	P.4.08 Metabolic syndrome, inflammation and oxidative stress as potential risk factors for affective disorders – a twin study. <i>European Neuropsychopharmacology</i> , 2019, 29, S706-S707.	1.6	0
1227	Considerations when selecting pharmacotherapy for nicotine dependence. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 245-250.	1.9	0
1228	Physicochemical quality of brown soybean preserve in function of maceration time and ascorbic acid. <i>Food Science and Technology</i> , 2020, 40, 250-257.	1.7	0
1229	What is the potential of statins in the treatment of depression?. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 307-309.	2.8	0
1230	Bridging the treatment gap: Psychedelics, prevention, pills and potions, psychotherapy and protest. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 221-222.	2.7	0
1231	The embryology of psychosis. <i>Lancet Psychiatry</i> , 2020, 7, 219-220.	7.6	0
1232	Major depressive disorders and bipolar disorders in older adults: Commentary on the RANZCP mood disorders guideline summaries. <i>Bipolar Disorders</i> , 2021, 23, 416-417.	2.4	0
1233	Confirmatory evaluation of the bipolar depression rating scale (BDRS) in a large sample of female patients with bipolar depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 85-91.	2.7	0
1234	796Is Mindfulness a more effective intervention than Psychoeducation for reducing Bipolar Disorder-related symptoms of depression?. <i>International Journal of Epidemiology</i> , 2021, 50, .	2.0	0
1235	The Clinical Global Impressions Scale Modified for Substance Use (CGI-SU) in patients with bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2006, 18, 278-279.	2.2	0
1236	Increased Soluble Fas and Fas Ligand Levels in Patients with Nonalcoholic Steatohepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, S122.	0.4	0
1237	The Ski oncoprotein regulates Hematopoietic Stem Cell Fitness and Functions as a Corepressor for Cfi1.. <i>Blood</i> , 2008, 112, 1403-1403.	1.4	0
1238	Selective Estrogen Receptor Modulator Treatment in Postmenopausal Women with Schizophrenia.. , 2010, , P1-203-P1-203.		0
1239	Glutamatergic antidepressants. , 2012, , 94-107.		0
1240	Difficult-to-treat depression. <i>Medical Journal of Australia</i> , 2012, 1, 4-5.	1.7	0
1241	Bipolar disorder. , 2017, , 151-170.		0
1242	School Improvement by Design. , 2021, , 105-126.		0

#	ARTICLE	IF	CITATIONS
1243	Editorial: A fresh look at mood and anxiety disorders: recent developments and emerging concepts. <i>Current Opinion in Psychiatry</i> , 2022, 35, 1-2.	6.6	0
1244	Supporting Dietary Change for the Treatment of Mood Disorders in Adults: How Can We Harness Digital Platforms?. <i>Psychiatric Annals</i> , 2022, 52, 62-66.	0.2	0
1245	Preface. , 0, , vii-vii.		0
1246	Introduction. , 0, , ix-xii.		0
1247	Bipolar disorder. , 0, , 1-20.		0
1248	Assessment and engagement. , 0, , 21-35.		0
1249	Insight, adaptation, and functional recovery. , 0, , 36-54.		0
1250	Medication adherence. , 0, , 55-64.		0
1251	Cognitive behavioral therapy interventions. , 0, , 65-97.		0
1252	Social rhythm regulation. , 0, , 98-104.		0
1253	Relationship issues and family work. , 0, , 105-116.		0
1254	Alcohol, substance abuse, and other comorbid disorders. , 0, , 117-130.		0
1255	Identifying early warning signs, preventing relapse, and termination of therapy. , 0, , 131-146.		0
1256	Transdiagnostic Associations between Anger Hostility and Chemokine Interferon-gamma Inducible Protein 10. <i>Clinical Psychopharmacology and Neuroscience</i> , 2024, 22, 285-294.	2.1	0
1257	A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial of adjunctive N-Acetylcysteine for treatment-resistant PTSD. <i>Psychiatry Research</i> , 2023, 327, 115398.	3.4	0
1258	Psychiatric sequelae after SARS-Cov-2 infection: Trajectory, predictors and associations in a longitudinal Australian cohort. <i>Acta Neuropsychiatrica</i> , 0, , 1-23.	2.2	0
1259	Comparing 12-Month Outcomes for Group CBT Versus Group CBT Plus Yoga for Depression and Anxiety: a Mixed-Methods Study. <i>International Journal of Mental Health and Addiction</i> , 0, , .	7.4	0
1260	Research Letter: What do Australian consumers with lived experience of bipolar disorder want from early intervention services?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2024, 58, 280-283.	2.7	0

#	ARTICLE	IF	CITATIONS
1261	The Mental Health Australia General Clinical Trials Network (MAGNET): The why, who and how?. Australian and New Zealand Journal of Psychiatry, 2024, 58, 195-197.	2.7	0
1262	Cytokines in hepatitis C-infected patients with or without opioid maintenance therapy. Acta Neuropsychiatrica, 0, , 1-7.	2.2	0
1263	Lithium use and bone health in women with bipolar disorder: A cross-sectional study. Acta Psychiatrica Scandinavica, 2024, 149, 332-339.	4.5	0
1264	SmartStim: An Artificial Intelligence Enabled Deep Brain Stimulation Device. IEEE Transactions on Medical Robotics and Bionics, 2024, 6, 674-684.	3.3	0
1265	Research Letter: The state of academic psychiatry in Aotearoa New Zealand and Australia: Data from a survey of the Royal Australian and New Zealand College of Psychiatrists membership. Australian and New Zealand Journal of Psychiatry, 2024, 58, 537-539.	2.7	0
1266	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023: Towards Personalized Approaches to Depression Treatment. Canadian Journal of Psychiatry, 0, , .	2.2	0
1267	Prior psychiatric morbidity and differential psychopharmacological treatment patterns: Exploring the heterogeneity of bipolar disorder in a nationwide study of 9594 patients. Bipolar Disorders, 0, , .	2.4	0
1268	Situation-Focused Coping: A Problem-Solving Approach. , 2024, , 37-47.		0
1269	Involving Family. , 2024, , 73-80.		0
1270	Building Secure Relational Networks. , 2024, , 57-65.		0
1271	Summary. , 2024, , 97-98.		0
1272	Developing a Crisis Plan. , 2024, , 27-36.		0
1273	Understanding Self-Harm and Starting the ATMAN Brief Intervention. , 2024, , 23-26.		0
1274	The ATMAN Brief Psychological Intervention. , 2024, , 9-14.		0
1275	Open-Ended Session. , 2024, , 67-71.		0
1276	Boosting Assertiveness Skills. , 2024, , 89-95.		0
1277	ATMAN Assessments. , 2024, , 15-22.		0
1278	Emotion-Focused Coping: Emotion Regulation. , 2024, , 49-55.		0

#	ARTICLE	IF	CITATIONS
1279	Substance Use. , 2024, , 81-87.		0
1280	Background. , 2024, , 1-7.		0
1281	Is a vegetarian diet beneficial for bipolar disorder? Relationship between dietary patterns, exercise and pharmacological treatments with metabolic syndrome and course of disease in bipolar disorder. Acta Psychiatrica Scandinavica, 0, , .	4.5	0
1282	Towards development of reliable criteria for atâ€risk states for bipolar disorders. Bipolar Disorders, 0, , .	2.4	0
1283	Treatment resistant but not irremediable. Bipolar Disorders, 0, , .	2.4	0